METHOD FOR TREATMENT AND PROPHYLAXIS OF CRS IN PATIENTS COMPRISING A COMBINATION OF BISPECIFIC ANTIBODIES BINDING TO CDS X CANCER CELL AND TNF ALPHA OR IL-6 INHIBITOR
20230146593 · 2023-05-11
Inventors
- Sophia K. Khaldoyanidi (Thousand Oaks, CA, US)
- Dirk NAGORSEN (Thousand Oaks, CA, US)
- Tara Arvedson (Thousand Oaks, CA, US)
- Suresh Agarwal (Thousand Oaks, CA, US)
- Vijay Vishesh Upreti (Thousand Oaks, CA, US)
- Steven Yea (Thousand Oaks, CA, US)
Cpc classification
C07K16/2863
CHEMISTRY; METALLURGY
A61K45/06
HUMAN NECESSITIES
C07K16/3069
CHEMISTRY; METALLURGY
C07K16/2809
CHEMISTRY; METALLURGY
C07K2319/30
CHEMISTRY; METALLURGY
A61K38/1793
HUMAN NECESSITIES
A61K2039/507
HUMAN NECESSITIES
C07K2317/30
CHEMISTRY; METALLURGY
A61K39/3955
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K2300/00
HUMAN NECESSITIES
A61K31/573
HUMAN NECESSITIES
C07K14/7151
CHEMISTRY; METALLURGY
A61K31/573
HUMAN NECESSITIES
International classification
A61K39/395
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
Abstract
The present invention relates to medical combination products comprising (i) at least one antibody construct comprising at least one domain which binds to a target antigen expressed on the surface of a cell and at least one other domain which binds to CD3 as well as (ii) at least one molecule that is inhibitor/antagonist of TNF/TNFR reducing TNF/TNFR signaling and/or an inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling, wherein a first dose of said inhibitor/antagonist is administered before administration of a first dose of said antibody construct. Furthermore, the invention provides therapeutic and preventive methods and medical uses of said combination products, as well as a kit comprising said at least one antibody construct and at least one antagonist/inhibitor of TNF or IL6 or its cognate receptor, wherein the interaction of said antagonist/inhibitor of TNF or an inhibitor/antagonist of IL6 with its cognate receptor reduces, mitigates, prevents, or treats cytokine release syndrome.
Claims
1. A method for the treatment of a disease, particularly cancer and/or for the prophylaxis, prevention, reduction, amelioration, and/or alleviation of adverse events associated with cancer immunotherapy, particularly with cancer immunotherapy engaging T cells via CD3 binding antibody constructs in a human patient, said method comprising (a) administering an antibody construct that binds selectively to a target antigen on a cancer cell and to human CD3 on the surface of a T cell, (b) administering an inhibitor/antagonist of TNF/TNFR reducing TNF/TNFR signaling, and/or administering an inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling, wherein a first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or a first dose of said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R according to (b) signaling is administered before administration of a first dose of said antibody construct (a) within a first period, said period ranging from 5 minutes to 7 days prior to administration of the antibody construct, particularly wherein said period is ranging from 15 minutes to 7 days prior to administration of the antibody construct.
2. The method of claim 1, wherein the antibody construct binds selectively to a target antigen on a target cell selected from the group comprising CD19, CD33, FLT3, PSMA, BCMA, Claudin 6, Claudin 18.2, Mucin 17, and DLL3.
3. The method of any one of claims 1 and 2, wherein said method comprises the prevention, prophylaxis, amelioration, reduction and/or alleviation of adverse events associated with cancer immunotherapy, particularly wherein these adverse events are selected from cytokine release syndrome (CRS) and tumor lysis syndrome (TLS), particularly in a patient at risk of developing CRS and/or TLS.
4. The method of any one of claims 1 to 3, wherein at least one further dose, particularly a second dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered before administration of said antibody construct.
5. The method of any one of claims 1 to 4, wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling (b) is administered following administration of said antibody construct.
6. The method of any one of claims 1 to 5, wherein a first dose, and optionally also at least one further dose, of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered within a first period before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of said antibody construct, and optionally wherein at least one dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
7. The method of any one of claims 1 to 6, wherein said first dose, and optionally also at least one further dose of said inhibitor of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, said period ranging from 30 minutes to 7 days prior to administration of the antibody construct, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
8. The method of any one of claims 1 to 7, wherein said first dose, and optionally also at least one further dose of said inhibitor of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, said period ranging from 30 minutes to 6 days prior to administration of the antibody construct, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
9. The method of any one of claims 1 to 8, wherein said first dose, and optionally also at least one further dose of said inhibitor of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, said period ranging from 30 minutes to 5 days prior to administration of the antibody construct, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
10. The method of any one of claims 1 to 9, wherein said first dose, and optionally also at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, said period ranging from 30 minutes to 4 days prior to administration of the antibody construct, wherein also said at least one optional further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
11. The method of any one of claims 1 to 10, wherein said first dose, and optionally also at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, said period ranging from 30 minutes to 3 days prior to administration of the antibody construct, wherein also said at least one optional further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
12. The method of any one of claims 1 to 11, wherein said first dose, and optionally also at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling (b) and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is selected from etanercept and/or tocilicumab, said period ranging from 30 minutes to 2 days prior to administration of the antibody construct, particularly wherein the target antigen is Flt3 or CD33, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
13. The method of any one of claims 1 to 12, wherein said first dose, and optionally also at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, said period ranging from 30 minutes to 1 day prior to administration of the antibody construct, particularly wherein the target antigen is Flt3 or CD33, more particularly wherein the target antigen is CD33, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
14. The method of any one of claims 1 to 13, wherein said first dose, and optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, wherein said period is shorter than the first period of administration of the inhibitor, and optionally wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
15. The method of any one of claims 1 to 14, wherein said first dose, optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and wherein optionally the at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also the further said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, wherein said second period is shorter than the first period of administration of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b), wherein the further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a period ranging from 30 minutes to 5 days, 30 minutes to 4 days, 30 minutes to 3 days, 30 minutest to 2 days, particularly 30 minutes to 1 day prior to administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct.
16. The method of any one of claims 1 to 15, wherein said first dose, optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling (b) and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, wherein said second period is shorter than the first period of administration of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b), wherein the further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a period ranging from 30 minutes to 5 days, 30 minutes to 4 days, 30 minutes to 3 days, 30 minutest to 2 days, particularly 30 minutes to 1 day prior to administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein the first dose and at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) comprise different quantities of inhibitor and/or different quantities of the antibody construct.
17. The method of any one of claims 1 to 16, wherein said first dose, optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein the first dose and at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) comprise identical quantities of inhibitor and/or identical quantities of the antibody construct.
18. The method of any one of claims 1 to 17, wherein said first dose, optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein another dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct within a period from 1 day to 7 days following a first administration of a dose of said antibody construct.
19. The method of any one of claims 1 to 18, wherein said first dose, optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein another dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct within a period from 1 day to 6 days following a first administration of a dose of said antibody construct.
20. The method of any one of claims 1 to 19, wherein said first dose, and optionally said also at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein another dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct within a period from 1 hour to 5 days following a first administration of a dose of said antibody construct.
21. The method of any one of claims 1 to 20, wherein said first dose, and optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein another dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct within a period from 1 hour to 4 days following a first administration of a dose of said antibody construct.
22. The method of any one of claims 1 to 21, wherein said first dose, and optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein another dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct within a period from 1 hour to 3 days following a first administration of a dose of said antibody construct.
23. The method of any one of claims 1 to 22, wherein said first dose, and optionally also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is/are administered before administration of said antibody construct, and optionally wherein at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct, wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a first period before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein also said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a second period before administration of the antibody construct, and optionally wherein said at least one other dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered within a third period following administration of said antibody construct, wherein another dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered following administration of said antibody construct within a period from 1 hour to 2 days following a first administration of a dose of said antibody construct.
24. The method of any one of claims 1 to 21, wherein said target antigen is CD33, particularly wherein the antibody construct comprises a first domain that comprises the CDR sequences as depicted in SEQ ID NOs: 317-319 and 323-325, and wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered about 1 day before administration of the antibody construct, particularly wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is selected from etanercept and/or tocilicumab, wherein said at least one further dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b) is administered about 4 days following administration of said antibody construct.
25. The method of any one of claims 1 to 21, wherein said target antigen is CD33, particularly wherein the antibody construct comprises a first domain that comprises the CDR sequences as depicted in SEQ ID NOs: 317-319 and 323-325, and wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is administered about 1 day before administration of the antibody construct, particularly wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling (b) is etanercept, wherein said at least one dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling (b), particularly etanercept, is administered about 4 days following administration of said antibody construct.
26. The method of any one of claims 1 to 23, wherein said target antigen is CD33, particularly wherein the antibody construct comprises a first domain that comprises the CDR sequences as depicted in SEQ ID NOs: 317-319 and 323-325, and wherein a first dose of said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is administered before administration of the antibody construct, particularly wherein inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling (c) is tocilicumab, wherein said dose is administered about 1 hour before administration of the antibody construct, optionally before administration of every dose of antibody construct.
27. The method of any one of claims 1 to 23, wherein said target antigen is Flt3, particularly wherein the antibody construct has a first domain comprising the CDR sequences depicted in SEQ ID NOs: 721 to 726, or wherein the first domain has VH and VL sequences as depicted in SEQ ID NOs: 727 and 728, and wherein the first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling (b) is administered about 2 days before administration of the antibody construct, wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling (b) is etanercept.
28. The method of any one of claims 1 to 23, wherein said target antigen is Flt3 particularly wherein the antibody construct has a first domain comprising the CDR sequences depicted in SEQ ID NOs: 721 to 726, or wherein the first domain has VH and VL sequences as depicted in SEQ ID NOs: 727 and 728, and wherein a first dose of said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is administered before administration of the antibody construct, particularly wherein inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling (c) is tocilicumab, wherein said dose is administered about 1 hour before administration of the antibody construct, optionally before administration of every dose of antibody construct.
29. The method of any one of claims 1 to 23, wherein said target antigen is BCMA, particularly wherein the antibody construct has a first domain comprising the sequence depicted in SEQ ID NO: 1293 or a derivative thereof comprising at least the 6 CDR in SEQ ID NO: 1285 to 1290 or comprising the VL and/or VH regions depicted in SEQ ID NO: 1291 and 1292, and wherein a first dose of said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is administered before administration of the antibody construct, particularly wherein inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling (c) is tocilicumab, wherein said dose is administered about 1 hour before administration of the antibody construct, optionally before administration of every dose of antibody construct.
30. The method of any one of claims 1 to 23, wherein said target antigen is Claudin 18.2 particularly wherein the antibody construct has a first domain comprising the sequence depicted in SEQ ID NO: 1294 or a derivative thereof comprising at least the 6 CDR comprised in SEQ ID NO: 1294 or comprising the VL and/or VH regions depicted in SEQ ID NO: 1294, and wherein a first dose of said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is administered before administration of the antibody construct, particularly wherein inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling (c) is tocilicumab, wherein said dose is administered about 1 hour before administration of the antibody construct, optionally before administration of every dose of antibody construct.
31. The method of any one of claims 1 to 23, wherein said target antigen is Mucin 17 particularly wherein the antibody construct has a first domain comprising the sequence depicted in SEQ ID NO: 1295 or a derivative thereof comprising at least the 6 CDR comprised in SEQ ID NO: 1295 or comprising the VL and/or VH regions depicted in SEQ ID NO: 1295, and wherein a first dose of said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is administered before administration of the antibody construct, particularly wherein inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling (c) is tocilicumab, wherein said dose is administered about 1 hour before administration of the antibody construct, optionally before administration of every dose of antibody construct.
32. The method of any one of the preceding claims, further comprising administering at least one corticosteroid and/or a non-glucocorticoidal compound.
33. The method of any one of the preceding claims, wherein said corticostoid is dexamethasone, and/or said non-glucocorticoidal compound is selected from the group comprising natalizumab, PPS, and minocylin.
34. The method of any one of claims 1 to 33, further comprising the administration of a corticoid compound, particularly dexamethasone, before administration of more that one dose of said antibody construct.
35. The method of any one of claims 1 to 23 and 32 to 34, wherein the target antigen is BCMA and the disease selected from a B cell disorder correlating with BCMA expression, a plasma cell disorder, particularly multiple myeloma, or an autoimmune disease.
36. The method of any one of claims 1 to 26 and 32 to 34, wherein the target antigen is Claudin 18.2 and the cancer is a gastrointestinal cancer selected from the group consisting of gastric cancer, esophageal cancer, gastroesophageal cancer, pancreatic cancer, and colorectal cancer.
37. The method of any one of claims 1 to 23 and 32 to 34, wherein the target antigen is Mucin 17 and the cancer is a gastrointestinal cancer selected from the group consisting of gastric cancer, esophageal cancer, gastroesophageal cancer, pancreatic cancer, and colorectal cancer.
38. The method of any one of claims 1 to 23 and 32 to 34, wherein the target antigen is PSMA and the cancer is a solid tumor, particularly prostate cancer or a cancer originating from a prostate cancer.
39. The method of any one of claims 1 to 23 and 32 to 34, wherein the target antigen is DLL3 and the cancer is a solid tumor selected from the group consisting of lung cancer, preferably SCLC, breast, cervical, colon, colorectal, endometrial, head and neck, liver, ovarian, pancreatic, prostate, skin, gastric, testis, thyroid, adrenal, renal, bladder, uterine, esophageal, urothelial and brain tumor or cancer, or a lymphoma, carcinoma, and sarcoma, and a metastatic cancer disease derived from any of the foregoing.
40. The method of any one of claims 1 to 25, 27, and 32 to 39, wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept, particularly wherein the dosage is administered subcutaneously.
41. The method of any one of claims 1 to 25, 27, and 32 to 40, wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept and the dosage is administered subcutaneously at a dose of between 10 mg to 100 mg.
42. The method of any one of claims 1 to 24, 26, and 32 to 39, wherein the inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is tocilizumab, particularly wherein the dosage is administered intravenously.
43. The method of any one of claims 1 to 24, 26, 32 to 39, and 42, wherein the inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling is tocilizumab and the dosage is administered intravenously or at 1 mg/kg to 20 mg/kg.
44. The method of any one of the preceding claims 1 to 43, wherein the adverse event associated with immunotherapy is associated with increased cytokine release of TNF, IL-1, MCP-1, and/or IL-6, and wherein the group of adverse events optionally further comprises a neurological reaction, particularly one or more selected from the group consisting of: confusion, ataxia, disorientation, dysphasia, aphasia, speech impairment, cerebellar symptoms, tremor, apraxia, seizure, grand mal convulsion, palsy, and balance disorder.
45. The method of any one of the preceding claims 1-44, wherein the domain of said antibody construct that binds to CD3, binds to human CD3 epsilon and to Callithrix jacchus or Saimiri sciureus CD3 epsilon.
46. The method of any one of the preceding claims 1 to 45, wherein a) the antibody construct is a single chain antibody construct, b) the first domain is in the format of an scFv, c) the second domain is in the format of an scFv, d) the first and the second domain are connected via a linker, and/or e) the antibody construct comprises a domain providing an extended serum half-life.
47. The method of any one of the preceding claims 1 to 46, wherein said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling and/or said inhibitor/antagonist of IL6/IL6R that reduces IL6/IL6R signaling according to (b), is selected from the group comprising small molecules, biological molecules, antibodies and derivatives thereof, and aptamers.
48. The method of any one of the preceding claims 1 to 25, 27, 32 to 41, 44 to 47, wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is selected from the group of TNF inhibitors/antagonists comprising etanercept, infliximab, adalimumab, certolizumab Pergol, and golimumab, particularly etanercept.
49. The method of any one of the preceding claims, wherein said patient is selected from the group of patients at risk of developing adverse events or having an intolerance to at least one of a group comprising corticosteroids, non-glucocorticoidal compounds, IL-6-inhibitors, IL-6R-inhibitors, and/or TNF/TNFR inhibitors different from an inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling according to claim 48.
50. The method of any one of the preceding claims, wherein said patient is selected from the group of patients at risk of developing adverse events or having an intolerance to corticosteroids, optionally also wherein the corticosteroid is dexamethasone.
51. The method of any one of the preceding claims, wherein the step of administering an antibody construct that binds selectively to a target antigen on a cancer cell and to human CD3 on the surface of a T cell is the first exposure of said antibody construct.
52. The method of any one of the preceding claims 1 to 50, wherein the step of administering an antibody construct that binds selectively to a target antigen on a cancer cell and to human CD3 on the surface of a T cell is a re-exposure of the patient to said antibody construct.
53. The method of any one of claims 1 to 34, comprising the administration of a corticoid compound, particularly dexamethasone, before administration of more than one dose of said antibody construct, wherein said antibody construct is selected from CD19, CD33, FLT3, PSMA, BCMA, Claudin 6, Claudin 18.2, Mucin 17, and DLL3, particularly CD33, PSMA or FLT3, and wherein the wherein a first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is administered before administration of a first dose of said antibody construct (a) within a first period, said period ranging from 5 minutes to 7 days prior to administration of the antibody construct, particularly wherein said period is ranging from 15 minutes to 7 days prior to administration of the antibody construct, and wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept.
54. The method of any one of claims 1 to 34 and 53, comprising the administration of a corticoid compound, particularly dexamethasone, before administration of more than one dose of said antibody construct, wherein said antibody construct is CD33, PSMA or FLT3, and wherein the wherein a first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is administered before administration of a first dose of said antibody construct (a) within a first period, said period ranging from 5 minutes to 7 days prior to administration of the antibody construct, particularly wherein said period is ranging from 15 minutes to 7 days prior to administration of the antibody construct, and wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept.
55. The method of any one of claims 1 to 34, comprising the administration of dexamethasone before administration of one dose of said antibody construct, wherein said antibody construct is CD33, and wherein the wherein a first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is administered before administration of a first dose of said antibody construct (a) within a first period, said period ranging from 5 minutes to 7 days prior to administration of the antibody construct, particularly wherein said period is ranging from 15 minutes to 7 days prior to administration of the antibody construct, and wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept.
56. The method of any one of claims 1 to 34, comprising the administration of dexamethasone before administration of one dose of said antibody construct, wherein said antibody construct is Flt3, and wherein the wherein a first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is administered before administration of a first dose of said antibody construct (a) within a first period, said period ranging from 5 minutes to 7 days prior to administration of the antibody construct, particularly wherein said period is ranging from 15 minutes to 7 days prior to administration of the antibody construct, and wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept.
57. The method of any one of claims 1 to 34, comprising the administration of dexamethasone before administration of one dose of said antibody construct, wherein said antibody construct is PSMA, and wherein the wherein a first dose of said inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is administered before administration of a first dose of said antibody construct (a) within a first period, said period ranging from 5 minutes to 7 days prior to administration of the antibody construct, particularly wherein said period is ranging from 15 minutes to 7 days prior to administration of the antibody construct, and wherein the inhibitor/antagonist of TNF/TNFR that reduces TNF/TNFR signaling is etanercept.
Description
DESCRIPTION OF THE FIGURES
[1060]
[1061]
[1062]
[1063]
[1064]
[1065]
[1066]
[1067] A better understanding of the present invention and of its advantages will be obtained from the following examples, offered for illustrative purposes only. The examples are not intended and should not be construed as to limit the scope of the present invention in any way.
Example 1
[1068] Immunocompetent C57BL/6 mice engineered to express human CD3 (huCD3 knock-in) were pretreated with either a control antibody or two different TNFα blocking agents, an anti-TNFα blocking antibody (anti-TNFα Ab) or a tumor necrosis factor receptor II-Fc fusion protein (TNFRII-Fc). These agents were administered once per day for two days prior to dosing with either an anti-mouse CD19 BiTE® molecule (100 μg/kg or 1000 μg/kg) that recognizes CD19 on B cells, or a negative control BiTE® molecule (n=5 animals per group). Serum cytokines were measured four hours after BiTE® treatment and B cell depletion was measured at 72 hours after BiTE® treatment. The engagement of T cells in vivo using the anti-mouse CD19-targeted BiTE® molecule resulted in activation of T cells, production of cytokines that could be measured in the serum, and depletion of B cells in the spleen. Administration of TNFα blocking reagents prior to BiTE® administration did not affect the ability of the BiTE® molecule to deplete B cells in the spleen (
Cytokine Measurements
[1069] Milliplex Mouse Cytokine/Chemokine kits (EMD Millipore) were used on Curiox 96w DropArray microplates per both manufacturers' protocols to test the cytokine levels in the original samples collected. Assays were performed such that contents of one EMD Millipore Milliplex kit was used in smaller amounts on 4 Curiox microplates. The lots of the Curiox plates and all items included in the Millipore kits were as shown in Table 1 below.
TABLE-US-00002 Description Cat# Kit lot# Pre-mixed blend of analytes MCYPMX32 3136598 Standard MXM8070-2 SC7N807-8K QC1 MXM6070-2 MCY-108 QC2 MXM6070-2 MCY-208 Serum Matrix MXMSM 3075213 Detection Antibodies MXM1070-3 3207309 Streptavidin-Phycoerythrin L-SAPE10 3216830 Assay Buffer L-AB 3231126 Curiox 96w drop Array #96-CC-BD- C96C2219135-B plates 05 Curiox Wash Buffer — 1x PBS, 0.1% BSA, 0.05% Tween20 (PBS 14190-136, lot 17765965)
Preparation of Curiox Items
[1070] All samples were run on four Curiox microplates. [1071] Two Curiox Humid Boxes were prepared with 8 paper towels and 100 mL PBS. [1072] Lid sponges on each of two Curiox plates were wetted with 12 mL PBS. [1073] Plates were blocked with 20 μL/well 1% BSA/PBS [1074] Plates were left inside humid box on a Titramax 1000 Shaker (Heidolph Instruments) at ˜400 rpm for 30 minutes
Preparation of Milliplex Reagents
Beads:
[1075] A premix of beads was used in this assay. Analytes IFNγ, IL-2, IL-6 and TNFα were read by the software and subsequently analyzed.
Quality Controls:
[1076] One vial of each Quality Control 1 and 2 was reconstituted with 250 μL ddH2O per vial, vortexed lightly (5 seconds), and allowed to sit at room temp for at least 10 minutes before being used.
Wash Buffer:
[1077] Curiox Wash Buffer (1×PBS, 0.1% BSA, 0.05% Tween20) was created by mixing. Each liter contains: [1078] 900 mL 1×PBS [1079] 100 mL 1% BSA in PBS [1080] 500 μL 10% Tween20 in PBS
Serum Matrix:
[1081] One vial of lyophilized serum matrix was freshly reconstituted with 2 mL Assay Buffer, left to sit at room temp for 10 minutes and then used according to protocol 5 μL per well in standards, quality control, and blank wells.
Serum Dilutions:
[1082] Each serum sample was assessed in duplicate and neat only with no dilutions.
Standard Reconstitution and Dilution:
[1083] One vial of cytokine standard was freshly reconstituted with 250 μL, ddH2O, vortexed lightly (5 seconds), and allowed to sit at room temperature for at least 10 minutes before being diluted and readied for the assay. Standard dilutions were then made at 1:2 such that 100 μL of higher concentrated standard was serially diluted into 100 μL assay buffer to create 13 total dilutions; highest concentration being 10,000 μg/mL, and lowest concentration at 2.4 μg/mL, for all analytes.
Immunoassay Procedure
[1084] The Curiox plates (currently in Block) were each washed 1×using the Curiox DropArray plate washer. Using reverse pipetting (for more accurate dispensing of pipet contents), the following were added to the plates using the plate layouts captured in ELN 20191022-00064. 5 μL bead mix was added per well to all wells. 5 μL Serum Matrix was added to Standards and Quality Control wells. 5 μL Assay Buffer was added to the sample wells. 5 μL Standards and QC controls were added to the appropriate wells. 5 μL sample was added to the appropriate wells. The plates were each mixed 10 seconds using a Vortex Genie plate mixer at 1000 rpm and then left to incubate in the Humid Boxes on a Titramax Shaker, with the magnet array, at ˜400 rpm overnight at 4° C. The following day, plates were washed 3×using the Curiox DropArray plate washer. 5 μL of biotinylated Detection Antibody was added to each well, plates were mixed 10 seconds using a Vortex Genie plate mixer at 1000 rpm, and then were left to incubate in the Humid Boxes, without magnet array, on a Titramax Shaker at ˜400 rpm for 1 hour at room temperature. 5 4 of Streptavidin-PE-labeled detection antibody was added to each well, plates were mixed 10 seconds using a Vortex Genie plate mixer at 1000 rpm and then were left to incubate in the Humid Boxes, without the magnet array, at ˜400 rpm shaking for 30 minutes at room temperature. The plates were again washed 3×using the Curiox DropArray plate washer. 20 μL of sheath fluid was added to each of the wells, plates were mixed 10 seconds using a Vortex Genie plate mixer at 1000 rpm and then were left to incubate in the Humid Boxes, without the magnet array, on a Titramax Shaker at ˜400 rpm for at least 5 minutes at room temperature. Individual well contents from each of the Curiox microplates were then mixed by pipetting up and down at least 10 times and transferred to the wells in a quadrant of a 384-well plate. After all Curiox plates' contents were transferred, 50 μL/well sheath fluid was added to each 384-well plate (now 70 μL/well), and the 384-well plates were mixed 30 seconds using a Vortex Genie plate mixer at 1000 rpm. The 384-well plate was read on a Luminex FlexMap 3D eader using xPONENT software.
Spleen Flow Cytometry Analysis
[1085] At the end of the study, animals were euthanized by carbon dioxide asphyxiation followed by physical cervical dislocation. Spleens were removed and collected in RPMI into individual wells of a 24-well plate. Spleens were pulverized through a 100 μm filter, rinsed with PBS, and 100 μL counting beads (Invitrogen, cat: 01-2222-42, lot:2037700, Carlsbad, Calif.) were added. The disaggregated spleens were then centrifuged at 500 rpm for 5 minutes at 4° C. After decanting the supernatant, the cell pellet was lysed with 1 mL RBC lysis buffer (Unity Lab Services, Amgen, South San Francisco) and quenched with FACS buffer containing FBS (2%). Cells were centrifuged a second time at 500 rpm for 5 minutes at 4° C. After decanting the supernatant, the cell pellet was resuspended in 1 mL FBS-free media. 200 μL of cell suspension was transferred to a 96-well V-bottom plate, live/dead dye exclusion (Invitrogen, Eugene, Oreg.) was added (at a 1:500 dilution) and the cells were incubated for 45 minutes at room temperature in the dark. Cells were washed, centrifuged as previously, and resuspended in 50 μL of Fc block (BD Biosciences, San Jose, Calif.) prior to staining with the following antibodies: BUV395 anti-mouse CD4 clone GK1.5, BV650 anti-mouse CD44 clone IM7, BV421 anti-mouse CD8a clone 53-6.7, PE anti-mouse CD25 clone PC61, BV711 anti-mouse CD62L clone MEL-14 (all from BD Biosciences, San Jose, Calif.), BV510 anti-mouse CD45 clone 30-F11, BV605 anti-mouse Thy1.2 clone 53-2.1, FITC anti-mouse CD19 clone 1D3/CD19, APC anti-mouse CD20 clone SA275A11, AF700 anti-mouse CD69 clone H1.2F3 (all from Biolegend, San Diego, Calif.) and Pe-Cy7 anti-mouse PD1 clone J43 (Thermo Fisher, San Diego, Calif.). Cells were washed and resuspended prior to analysis on a FACSymphony flow cytometer (BD Biosciences, San Jose, Calif.).
Statistical Analysis
[1086] Graphs were generated, and data analysis was performed using GraphPad Prism software (version 7.04, Lo Jolla, Calif.). Mean serum cytokine levels and B cell counts (n=5 animals per group) were expressed as the mean±standard deviation. The p value of 0.05 was used to determine significant differences between all groups using a one-way ANOVA with Tukey's test (GraphPad Prism).
Example 2
[1087] Female BALB/cJ Rj mice (n=10/group) were treated with either vehicle or the BiTE® antibody construct muS110, directed against murine Epithelial Cell Adhesion Molecule for 2 days (Table 2). Animals in group 3 were pre-treated with etanercept (Enbrel) on days −2 and −1 as well as 1 hour before each muS110 administration. Animals in group 4 were administered an anti-IL6 monoclonal antibody (MP5-20F3, BD) on day −1 and one hour before each muS110 treatment. Blood samples were collected 4 and 24 hours after each vehicle and muS110 administration and serum concentrations of IL-6, TNF and MCP1 were determined using the BD™ CBA Mouse Enhanced Sensitivity Flex Set System (Becton Dickinson, BD) in accordance to the manufacturer's instructions (Table 2).
TABLE-US-00003 TABLE 2 Study Design Route of Administra- Treatment Group Compound Dosages tion Schedule* 1 Vehicle — i.v. Days: 1, 2 2 muS110 0.05 g/kg/d i.v. Days: 1, 2 3 Enbrel + Enbrel*: 10 Enbrel: Enbrel: muS110 mg/kg/d i.p. days −2, −1, muS110: 0.05 muS110: 1, 2 mg/kg/d i.v. muS110: days 1, 2 4 Anti-IL6 + Anti-IL6: 2.5 mAb: i.v. Anti-IL6: muS110 mg/kg/d muS110: days −1, 1 muS110: 0.05 i.v. muS110: days 1, mg/kg/d 2 Etanercept (Enbrel*) and the anti-IL6 monoclonal antibody were administered 1 hour before muS110 treatment on days 1 and 2.
In Vitro Anti-TNF Assay
[1088] Cytotoxicity, T-cell activation (CD69 upregulation) and cytokine release were determined in multiparametric cytotoxicity assays. Redirected T cell cytotoxicity was evaluated by flow cytometry using isolated human CD3+ T cells as effector cells and Epithelial Cell Adhesion Molecule (EpCAM)-expressing KatoIII tumor cells as target cells. Effector and target cells were co-cultured at an E:T cell ratio of 10:1 and serial dilutions of BiTE® antibody construct AMG110, directed against murine Epithelial Cell Adhesion Molecule in the absence or presence of an anti-TNF monoclonal antibody (BD) or the respective isotype control. AMG 110-mediated redirected target cell lysis was determined after 24, 48 and 72 hours (as shown in
BiTE® Molecule Induced MCP-1 Release Blocked by Etanercept (Enbrel)
[1089] Human umbilical vein endothelial cells (HUVEC) were co-cultured with CD19-expressing NALM-6 cells and human PBMC and increasing concentrations of BiTE® antibody construct blinatumumab (AMG 103) against CD19 in the absence or presence of etanercept. MCP-1 concentrations were determined with the BD Cytometric CBA human MCP-1 Flex set system (BD, Germany after 2 and hours, respectively according to the manufacturer's instructions and are shown in
Blinatumumab VCAM Assay
[1090] The effect of blinatumumab (AMG 103) on T cell activation and the induction of VCAM-1 on endothelial cells was analyzed in co-cultures of HUVEC, isolated T cells and CD19-expressing NALM-6 target cells. VCAM-1 expression on CD31+ HUVEC was analyzed by flow cytometry. The T cell activation marker VCAM-1 was up-regulated by AMG 103, which was sensitive to etanercept, indicating the potential role of TNF in BiTE® molecule-mediated endothelial activation (
Example 3
[1091] Results with the antibody construct blinatumomab (CD19×CD3) demonstrate that TNF levels increased rapidly after the blinatumomab in cycle 1, reaching maximum levels within 2 hours, and reach peak levels earlier than other cytokines. CRS symptoms seem to be mediated by cytokines including interleukin-6 (IL-6) and TNF, tocilizumab and etanercept are evaluated, which block IL-6 and TNF, respectively, as separate premedications for CRS prophylaxis in subjects with RJR AML. Blocking TNF with etanercept premedication may prevent CRS or decrease the frequency and severity of CRS symptoms.
[1092] In a clinical study that is performed as described in study NCT02520427 (clinicaltrials.gov) in patients that have relapsed/refractory Acute Myeloid Leukemia, a recombinant monoclonal bispecific T-cell engager (BITE®) antibody construct directed against CD33 on target cells that simultaneously binds to CD3 on T cells (CD33×CD3-BiTE) was investigated. Previously, dexamethasone premedication was used for prophylaxis of CRS 1 hour before CD33×CD3-BiTE molecule administration. However, dexamethasone is a known immunosuppressant that may have an influence on the efficacy of said antibody construct.
[1093] Because increased serum IL-6 levels may contribute to the development of CRS symptoms, blocking interactions of IL-6 with its receptor (IL-6R) using tocilizumab as a premedication to prevent CRS or decrease the frequency and severity of CRS symptoms. IL-6 levels increase within first 6 hours following CD33×CD3-BiTE administration. Thus, tocilizumab was given to subjects 1 hour prior to CD33×CD3-BiTE administration to allow a blockade of the pro-inflammatory effects mediated by IL-6 upon the increase of its levels. Tocilizumab as a premedication for CRS prophylaxis was evaluated at the dose approved for treatment of CRS (8 mg/kg administered intravenously).
[1094] Further, pretreatment with etanercept to block the biological effects of TNF, which is released by T cells in response to CD33×CD3-BiTE treatment, was evaluated. Etanercept was administered subcutaneously (SC) at the approved dose of 50 mg on days −1 and 4 relative to the first dose of CD33×CD3-BiTE. This dose and timing were selected based on the PK properties of etanercept (slow absorption with mean±SD time of maximum concentration [tmax] of 69±34 hours; half-life of 102±30 hours) (Enbrel US Prescribing Information; Zhou et al, 2011), and on the direct relationship between the PK and PD of etanercept. Specifically, within 24 hours of etanercept administration, there is a significant increase in the inactive form of TNF (Madhusudan et al, 2005) and a decrease in IL-6 concentrations (Sato et al, 2011). The etanercept concentrations achieved from a 50-mg dose were expected to be within the dose target range (ie, 0.5 to 2 μg/mL as established for patients with rheumatoid arthritis; Breedveld et al, 2018) before the first dose of CD33×CD3-BiTE was administered on day 1 and remained above the lower target range up to day 14. Comparable peak TNF concentrations after administration of the BiTE antibody constructs blinatumomab and a half-life extended CD33×CD3-BiTE-binding T-cell engaging antibody construct have been observed in patients with cancer (30 to 60 μg/mL) and rheumatoid arthritis (mean peak levels of 32.9 and 31.6 μg/mL) (Nagele et al, 2017; Ebrahimi et al, 2009; Manicourt et al, 1993). Accordingly, an etanercept target range of 0.5 to 2 μg/mL was expected to provide adequate TNF inhibition and mitigate the CRS risk associated with administration of the first dose of CD33×CD3-BiTE.
[1095] Prior to administration of CD33×CD3-BiTE at increasing doses, subjects with R/R AML received tocilizumab (group 1) or etanercept (group 2) instead of dexamethasone. Tocilizumab (8 mg/kg IV) was administered on the first day of each cycle 1 hour before the first dose of AMG 330; etanercept (50 mg SC) was administered on study days −1 and 4.
[1096] Each premedication treatment group comprised a total of 6 evaluable subjects. Within each group, 3 subjects were initially enrolled and administered tocilizumab (8 mg/kg) or etanercept (50 mg) premedication as described above followed by treatment with CD33×CD3-BiTE. For these initial 3 subjects in each group, once no more than 1 dose-limiting toxicity (DLT) was observed within the DLT window, then the study was expanded to enroll 6 subjects for that group. If 2 subjects had a DLT in either group, then, upon resolution of the adverse event, these subjects proceeded with a combination of tocilizumab plus dexamethasone (group 1) or etanercept plus dexamethasone (group 2). The remaining subjects for the group for treatment were treated with the combination regimen (ie, tocilizumab plus dexamethasone [group 1] or etanercept plus dexamethasone [group 2]) for CRS prophylaxis. If no more than 1 DLT was observed in the 6 evaluable subjects in either group, then the premedication used in that group was considered safe and tolerable, substudy 2, in which either tocilizumab or etanercept were evaluated as single agent for CRS prophylaxis was initiated.
[1097] Subjects who received tocilizumab or etanercept prior to administration of AMG 330 were monitored for CRS using the guidance currently described in Protocol 20120252. Briefly, subjects were monitored for clinical signs (e.g., fever, hypotension, tachycardia, dyspnea, tremors) and laboratory changes (eg, transaminase increase) which may be related to CRS. If a subject treated with CD33×CD3-BiTE at the 10-μg step dose level developed grade 2 or higher CRS, the subject continued the study using both tocilizumab and dexamethasone or etanercept and dexamethasone as premedication for CRS prophylaxis to assess whether a combination regimen is more effective than monotherapy for CRS prophylaxis. When a subject treated with CD33×CD3-BiTE at the target dose level developed grade 3 or higher CRS, CD33×CD3-BiTE was stopped until the severity of CRS decreases to grade 1, at which point the subject was able to restart the study using both tocilizumab and dexamethasone or etanercept and dexamethasone as premedication for CRS prophylaxis.
[1098] For those patients from study part 1 in which it was shown that CRS incidence/severity with tocilizumab or etanercept is similar to that observed with dexamethasone premedication (ie, 1 DLT and some reported grade 2 CRS events in the etanercept or tocilizumab group), a mini-step approach was tested to improve CRS onset dynamics. With this approach, subjects were treated with tocilizumab or etanercept premedication followed by CD33×CD3-BiTE administered with daily mini-step doses, followed by the target dose.
[1099] For those patients from study part 1 in which it was shown that CRS incidence/severity with tocilizumab or etanercept was lower than that with dexamethasone premedication (ie, no DLTs and no reported grade 2 CRS events in the etanercept or tocilizumab group), a maxi-step approach was tested to reach the efficacious dose faster. With this approach, subjects were treated with tocilizumab or etanercept premedication followed by administration of CD33×CD3-BiTE at increasing doses.
[1100] For those patients from study part 1 in which combination regimen (ie, tocilizumab and dexamethasone or etanercept and dexamethasone as premedication for CRS prophylaxis) was needed, a similar approach has been used to determine whether the mini-step or maxi-step approach should be tested in part 2 for the combination regimen.
Example 4
[1101] In this example, it is further evaluated, if pretreatment with etanercept will block the biological effects of TNF, which is released by T cells in response to treatment with an antibody construct binding FLT3 and CD3 (Flt3×CD3-BiTE). TNF levels after Flt3×CD3-BiTE infusion are consistent with that of blinatumomab, with TNF-α and IL-6 peak levels seen at 6 hour collection time points after Flt3×CD3-BiTE dosing. Collectively, these data demonstrate consistent and reproducible cytokine release after BiTE therapy infusion.
[1102] Etanercept at 50 mg dose was given on day minus 2 relative to the first dose of Flt3×CD3-BiTE. This dose and timing were selected based on the PK/PD properties of etanercept, which showed slow absorption (mean±SD time of maximum concentration [tmax] of 69±34 hours) (Enbrel US Prescribing Information; Zhou et al, 2011), and is expected to provide maximal TNF inhibition by the time of Flt3×CD3-BiTE dosing.
[1103] As mentioned above in Example 3, approximately similar peak TNF concentrations after administration of the BiTE antibody constructs Flt3×CD3-BiTE, blinatumomab, and others have been observed in patients with cancer (30 to 60 μg/mL) and rheumatoid arthritis (mean peak levels of 32.9 and 31.6 μg/mL) (Nagele et al, 2017; Ebrahimi et al, 2009; Manicourt et al, 1993). These results suggest that an etanercept target range of 0.5 to 2 μg/mL provides adequate TNF inhibition and mitigate the CRS risk associated with administration of the first dose of Flt3×CD3-BiTE.
[1104] During dose escalation, a separate parallel substudy evaluated the effect of etanercept with dexamethasone and etanercept alone for CRS prophylaxis. This substudy will run in parallel to the primary dose escalation, which currently requires administration of a prophylactic steroid dose (8 mg IV dexamethasone) within 1 hour prior to start of Flt3×CD3-BiTE infusion, and prior to each dose step of Flt3×CD3-BiTE, to mitigate CRS.
[1105] This substudy tested as to whether the inhibition of TNF lead to decreased rates and/or grades of CRS symptoms by blocking this early and necessary cytokine. The results of this substudy assess better CRS risk mitigation strategies for subjects and obviate the need for prophylactic dexamethasone.
[1106] Six subjects received an initial dose of Flt3×CD3-BiTE and etanercept/dexamethasone prophylaxis and were monitored for decreased or similar rates or grades of CRS (overall CRS rate <60%, or grade ≥2 CRS in <40% of subjects) compared to subjects who received only dexamethasone premedication. Subsequently, higher dose levels of Flt3×CD3-BiTE that had been cleared as safe and tolerable, were tested in an additional 3-6 subjects. These additional 3-6 subject who received Flt3×CD3-BiTE were monitored for the occurrence of decreased or similar rates or grades of CRS (overall CRS rate <75%, or grade ≥2 CRS in <75% of subjects), before etanercept as CRS prophylaxis was tested in an additional 3-6 subjects at the same dose of Flt3×CD3-BiTE.
[1107] Further, 6 subjects who received an initial dose of the Flt3×CD3-BiTE and etanercept/dexamethasone prophylaxis were monitored for the occurrence of decreased or similar rates or grades of CRS (overall CRS rate <60%, or grade ≥2 CRS in <40% of subjects) compared to subjects who received only dexamethasone premedication, and subsequently testing of only etanercept as CRS prophylaxis in an additional 3-6 subjects at the same dose cohort level of Flt3×CD3-BiTE was performed.
[1108] During dose escalation, a separate parallel substudy evaluated subjects to test the effect of etanercept with dexamethasone and etanercept alone for CRS prophylaxis. This substudy was run in parallel to the primary dose escalation, which required administration of a prophylactic steroid dose (8 mg IV dexamethasone) within 1 hour prior to start of Flt3×CD3-BiTE infusion prior to each dose step of Flt3×CD3-BiTE, to mitigate CRS. This substudy tested the hypothesis that inhibition of TNF leads to decreased rates and/or grades of CRS symptoms by blocking this early and necessary cytokine.
Example 5
[1109] Etanercept Prophylaxis for PSMA-targeting BiTE related CRS in humans: Etanercept premedication occurred within two days before BiTE administration to assess whether prophylaxis with the TNF-α inhibitor decreases the frequency and severity of CRS without compromising the efficacy of the BiTE. In an initial cohort of 6 to 8 subjects, the PSMA-targeting BiTE is administered. In addition to dexamethasone prophylaxis, subjects in the cohort received prophylaxis with etanercept (50 mg subcutaneously [SC]) two days prior to each dose of PSMA-targeting BiTE in the first administration cycle. This dose and timing was selected based on the PK properties of etanercept (slow absorption with mean SD time of maximum concentration [tmax] of 69±34 hours; half-life of 102 f 30 hours) (Enbrel Package Insert, 2017; Zhou et al, 2011).
[1110] Subject incidence of safety events, including dose-limiting toxicities (DLTs), serious adverse events (SAEs), and adverse events leading to treatment discontinuation or dose reduction, will be reviewed when at least 3 DLT-evaluable subjects complete the DLT window. Subjects receiving three individual increasing doses of PSMA-targeting BiTE with etancercept prophylaxis experienced 1 DLT/SAE (grade 3 (G3) thrombocytopenia), 1 SAE (Grade 3 (G3) Afib), 0 dose reductions, 1 discontinuation (tolerability), CRS events in cycle 1: 4 grade 2 (G2), no grade 3/4 (G3/4). Etanercept prophylaxis improves CRS safety profile compared with no premedication or premedication with tocilizumab (8 mg/kg) given two hours before administration of the first dose of the PSMA-targeting BiTE. In the latter group 1 DLT/SAE (G3 Hypoacusis), 2 SAE (grade 3 (G3) Pruritus, grade 2/3 (G2/G3) CRS), 2 dose reductions, 2 discontinuations (disease progression), and CRS events in cycle 1: 4 grade 1 (G1), 7 grade 2 (G2), 4 grade 3 (G3) were observed. In the etanercept prophylaxis group the PSMA-targeting BiTE was administered at the same dosages and frequency as in the group without etanercept prophylaxis.
Example 6
[1111] Adult patients with R/R AML received one cycle of continuous IV infusions of CD33×CD3 BiTE® molecules at increasing doses (10 μg, 60 μg and 240 μg on days 1, 3 and 6) preceded by administration of either 50 mg etanercept subcutaneously (about 24 hours prior to the initial administration of the 10 μg BiTE-treatment) or 8 mg dexamethasone IV (about 30 minutes prior to the initial administration of the 10 μg BiTE-treatment).
[1112] Etanercept-mediated CRS prevention is at least comparable to or even slightly better than CRS prevention with dexamethasone. Surprisingly, the duration of CRS in patients treated with etanercept for CRS prophylaxis as compared to dexamethasone is considerably shorter as shown in Table 3.
TABLE-US-00004 (a) Frequency and (b) dura- (a) Frequency and (b) dura- Number of tion (hrs) of CRS events in tion (hrs) of CRS events in patients etanercept-treated group dexamethasone-treated group 4 (a) 7 CRS events (1.75 per — patient) (b) average duration: 12 hrs 6 — (a) 14 CRS events (2.3 per patient) (b) average duration: 58 hrs
TABLE-US-00005 SEQ ID Format/ NO Designation Source Amino acid sequence 1 CD3ϵ ECD human QDGNEENGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIGGDED DKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCEN CNEND 2 CD3ϵ ECD pos. 1-27 human QDGNEENGGITQTPYKVSISGTTVILT 3 CDR-L1 of H2C artificial GSSTGAVTSGYYPN 4 CDR-L2 of H2C artificial GTKFLAP 5 CDR-L3 of H2C artificial ALWYSNRWV 6 CDR-L1 of E2M artificial RSSTGAVTSGYYPN 7 CDR-L2 of E2M artificial ATDNRPS 8 CDR-L3 of E2M artificial ALWYSNRWV 9 CDR-L1 of F12Q artificial GSSTGAVTSGNYPN 10 CDR-L2 of F12Q artificial GTKFLAP 11 CDR-L3 of F12Q artificial VLWYSNRWV 12 CDR-H1 of F6A artificial IYAMN 13 CDR-H2 of F6A artificial RIRSKYNNYATYYADSVKS 14 CDR-H3 of F6A artificial HGNFGNSYVSFFAY 15 CDR-H1 of H2C artificial KYAMN 16 CDR-H2 of H2C artificial RIRSKYNNYATYYADSVKD 17 CDR-H3 of H2C artificial HGNFGNSYISYWAY 18 CDR-H1 of H1E artificial SYAMN 19 CDR-H2 of H1E artificial RIRSKYNNYATYYADSVKG 20 CDR-H3 of H1E artificial HGNFGNSYLSFWAY 21 CDR-H1 of G4H artificial RYANN 22 CDR-H2 of G4H artificial RIRSKYNNYATYYADSVKG 23 CDR-H3 of G4H artificial HGNFGNSYLSYFAY 24 CDR-H1 of A2J artificial VYANN 25 CDR-H2 of A2J artificial RIRSKYNNYATYYADSVKK 26 CDR-H3 of A2J artificial HGNFGNSYLSWWAY 27 CDR-H1 of E1L artificial KYAMN 28 CDR-H2 of E1L artificial RIRSKYNNYATYYADSVKS 29 CDR-H3 of E1L artificial HGNFGNSYTSYYAY 30 CDR-H1 of E2M artificial GYANN 31 CDR-H2 of E2M artificial RIRSKYNNYATYYADSVKE 32 CDR-H3 of E2M artificial HRNFGNSYLSWFAY 33 CDR-H1 of F7O artificial VYAMN 34 CDR-H2 of F7O artificial RIRSKYNNYATYYADSVKK 35 CDR-H3 of F7O artificial HGNFGNSYISWWAY 36 CDR-H1 of F12Q artificial SYAMN 37 CDR-H2 of F12Q artificial RIRSKYNNYATYYADSVKG 38 CDR-H3 of F12Q artificial HGNFGNSYVSWWAY 39 CDR-H1 of I2C artificial KYAMN 40 CDR-H2 of I2C artificial RIRSKYNNYATYYADSVKD 41 CDR-H3 of I2C artificial HGNFGNSYISYWAY 42 CDR-L2 of H2C artificial GTKFLAP 43 CDR-L3 of H2C artificial ALWYSNRWV 44 CDR-H1 of H2C artificial KYAMN 45 CDR-L1 of H1E artificial GSSTGAVTSGYYPN 46 CDR-L2 of H1E artificial GTKFLAP 47 CDR-L3 of H1E artificial ALWYSNRWV 48 CDR-H1 of H1E artificial SYAMN 49 CDR-H2 of H1E artificial RIRSKYNNYATYYADSVKG 50 CDR-H3 of H1E artificial HGNFGNSYLSFWAY 51 CDR-L1 of G4H artificial GSSTGAVTSGYYPN 52 CDR-L2 of G4H artificial GTKFLAP 53 CDR-L3 of G4H artificial ALWYSNRWV 54 CDR-L1 of A2J artificial RSSTGAVTSGYYPN 55 CDR-L2 of A2J artificial ATDMRPS 56 CDR-L3 of A2J artificial ALWYSNRWV 57 CDR-L1 of E1L artificial GSSTGAVTSGYYPN 58 CDR-L2 of E1L artificial GTKFLAP 59 CDR-L3 of E1L artificial ALWYSNRWV 60 CDR-L1 of F7O artificial GSSTGAVTSGYYPN 61 CDR-L2 of F7O artificial GTKFLAP 62 CDR-L3 of F7O artificial ALWYSNRWV 63 CDR-L1 of I2C artificial GSSTGAVTSGNYPN 64 CDR-L2 of I2C artificial GTKFLAP 65 CDR-L3 of I2C artificial VLWYSNRWV 66 VL of H2C artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 67 VL of E2M artificial QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLI GATDMRPSGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 68 VL of F12Q artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF GGGTKLTVL 69 VL variant of H2C artificial ELVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 70 VL variant of A2J artificial ELVVTQEPSLTVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLI GATDMRPSGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 71 VL variant of F12Q artificial ELVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF GGGTKLTVL 72 VH of F6A artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNIYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSFFAYWGQGTLVTVSS 73 VH of H2C artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSS 74 VH of H1E artificial EVQLVESGGGLEQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSFWAYWGQGTLVTVSS 75 VH of G4H artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNRYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSYFAYWGQGTLVTVSS 76 VH of A2J artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSWWAYWGQGTLVTVSS 77 VH of E1L artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYTSYYAYWGQGTLVTVSS 78 VH of E2M artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNGYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKERFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HRNFGNSYLSWFAYWGQGTLVTVSS 79 VH of F7O artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISWWAYWGQGTLVTVSS 80 VH of F12Q artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSWWAYWGQGTLVTVSS 81 VH of I2C artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSS 82 VH of F12q artificial EVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVR HGNFGNSYVSWWAYWGQGTLVTVSS 83 VH variant of F6A artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNIYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSFFAYWGQGTLVTVSS 84 VH variant of H2C artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSS 85 VH variant of H1E artificial EVQLLESGGGLEQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSFWAYWGQGTLVTVSS 86 VH variant of G4H artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNRYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSYFAYWGQGTLVTVSS 87 VH variant of A2J artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSWWAYWGQGTLVTVSS 88 VH variant of E1L artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYTSYYAYWGQGTLVTVSS 89 VH variant of E2M artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNGYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKERFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HRNFGNSYLSWFAYWGQGTLVTVSS 90 VH variant of F7O artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISWWAYWGQGTLVTVSS 91 VH variant of F12Q artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSWWAYWGQGTLVTVSS 92 VH variant of I2C artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSS 93 VL of F6A artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 94 VL of H1E artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 95 VL of G4H artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 96 VL of A2J artificial QTVVTQEPSLTVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLI GATDMRPSGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 97 VL of E1L artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 98 VL of F7O artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVF GGGTKLTVL 99 VL of I2C artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF GGGTKLTVL 100 VL of F12q artificial QTVVTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLI GGTKFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVF GGGTKLTVL 101 scFv of F6A artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNIYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSFFAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 102 scFv of H2C artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 103 scFv of H1E artificial EVQLVESGGGLEQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSFWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 104 scFv of G4H artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNRYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSYFAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 105 scFv of A2J artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLIGATDMRPSGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 106 scFv of E1L artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYTSYYAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 107 SCEV of E2M artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNGYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKERFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HRNFGNSYLSWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLIGATDMRPSGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 108 SCEV of F7O artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 109 SCEv of F12Q artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 110 scFv of I2C artificial EVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 111 scFv of F12q artificial EVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVR HGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 112 scFv variant of F6A artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNIYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSFFAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 113 scFv variant of H2C artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 114 SCEV variant of H1E artificial EVQLLESGGGLEQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSFWAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 115 SCEV variant of G4H artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNRYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSYFAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 116 SCEV variant of A2J artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYLSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLIGATDMRPSGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 117 scFv variant of E1L artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKSRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYTSYYAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 118 scFv variant of E2M artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNGYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKERFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HRNFGNSYLSWFAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCRSSTGAVTSGYYPNWVQQKPGQAPRGLIGATDMRPSGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 119 scFv variant of F7O artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNVYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKKRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGYYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCALWYSNRWVFGGGTKLTVL 120 scFv variant of artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNSYAMNWVRQAPGKGLEWVAR F12Q IRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 121 SCEV variant of I2C artificial EVQLLESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVAR IRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVR HGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSELVVTQEPSL TVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGT PARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 122 20A2 VH CDR1 artificial NYGMH 123 20A2 VH CDR2 artificial LIWYDGSKKYYADSVKG 124 20A2 VH CDR3 artificial DPSSLTGSTGYYGMDV 125 20A2 VL CDR1 artificial SGDKLGDKYAC 126 20A2 VL CDR2 artificial QDRKRPS 127 20A2 VL CDR3 artificial QAWDSSTEV 128 20A2 light chain artificial MAWALLLLTLLTQGTGSWASYELTQPPSVSVSPGQTASITCSGDKLGDKY ACWYQQKPGQSPVLVIYQDRKRPSGIPERFSGSNSGNTATLTISGTQAMD EADYYCQAWDSSTEVFGGGT KLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKAD SSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST VEKTVAPTECS 129 20C1 VH CDR1 artificial SYDMS 130 20C1 VH CDR2 artificial LISGGGSNTYYADSVKG 131 20C1 VH CDR3 artificial PSGHYFYAMDV 132 20C1 VL CDR1 artificial RASQGISNWLA 133 20C1 VL CDR2 artificial AASSLQS 134 22D4 VH CDR1 artificial DYSMS 135 22D4 VH CDR2 artificial GINWNGGRTRYADSVKG 136 22D4 VH CDR3 artificial EFNNFESNWEDP 137 22D4 VL CDR1 artificial SGDALPKKYAY 138 22D4 VL CDR2 artificial EDSKRPS 139 22D4 VL CDR3 artificial YSTDSSGNHRV 140 20C1.006 VH CDR1 artificial SYDMS 141 20C1.006 VH CDR2 artificial LISGGGSNTYYAESVKG 142 20C1.006 VH CDR3 artificial PSGHYFYAMDV 143 20C1.006 VL CDR1 artificial RASQGISNWLA 144 20C1.006 VL CDR2 artificial AASSLQS 145 20C1.006 VL CDR3 artificial QQAESFPHT 146 20C1.009 VH CDR1 artificial SYDMS 147 20C1.009 VH CDR2 artificial LISGGGSQTYYAESVKG 148 20C1.009 VH CDR3 artificial PSGHYFYAMDV 149 20C1.009 VL CDR1 artificial RASQGISNWLA 150 20C1.009 VL CDR2 artificial AASSLQS 151 20C1.009 VL CDR3 artificial QQAESFPHT 152 20A2.003 VH CDR1 artificial NYGMH 153 20A2.003 VH CDR2 artificial LIWYDASKKYYAESVKG 154 20A2.003 VH CDR3 artificial DPSSLTGSTGYYGMDV 155 20A2.003 VL CDR1 artificial SGDKLGDKYAS 156 20A2.003 VL CDR2 artificial QDRKRPS 157 20A2.003 VL CDR3 artificial QAFESSTEV 158 22D4.006 VH CDR1 artificial DYSMS 159 22D4.006 VH CDR2 artificial GINWNGGRTRYADAVKG 160 22D4.006 VH CDR3 artificial EFNNFESNWFDP 161 22D4.006 VL CDR1 artificial SGDALPKKYAY 162 22D4.006 VL CDR2 artificial EDAKRPS 163 22D4.006 VL CDR3 artificial YSTDASGNHRV 164 22D4.017 VH CDR1 artificial DYSMS 165 22D4.017 VH CDR2 artificial GINWNAGRTRYADAVKG 166 22D4.017 VH CDR3 artificial EFNNFESNWFDP 167 22D4.017 VL CDR1 artificial SGDALPKKYAY 168 22D4.017 VL CDR2 artificial EDAKRPS 169 22D4.017 VL CDR3 artificial YSTDASGNHRV 170 20A2 VH artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAL IWYDGSKKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAAYYCARDP SSLTGSTGYYGMDVWGQGTTVTVSS 171 20A2 VL artificial SYELTQPPSVSVSPGQTASITCSGDKLGDKYACWYQQKPGQSPVLVIYQD RKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAWDSSTEVFGGG TKLTVL 172 20C1 VH artificial EVQLLESGGGLVQPGGALRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSL ISGGGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPS GHYFYAMDVWGQGTTVTVSS 173 20C1 VL artificial DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFA ASSLQSGVPSRFGGSGSGTDFTFTISSLQPEDFATYYCQQADSFPHTFGG GTKVEIK 174 22D4 VH artificial EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSG INWNGGRTRYADSVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREF NNFESNWFDPWGQGTLVTVSS 175 22D4 VL artificial SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKSGQAPVLVISED SKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDSSGNHRVFG GGTKLTVL 176 20C1.006 VH artificial EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSL ISGGGSNTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPS GHYFYAMDVWGQGTTVTVSS 177 20C1.006 VL artificial DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGG GTKVEIK 178 20C1.009 VH artificial EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYDMSWVRQAPGKGLEWVSL ISGGGSQTYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCASPS GHYFYAMDVWGQGTTVTVSS 179 20C1.009 VL artificial DIQMTQSPSSVSASVGDRVTITCRASQGISNWLAWYQQKPGKAPKLLIFA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQAESFPHTFGG GTKVEIK 180 20A2.003 VH artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSNYGMHWVRQAPGKGLEWVAL IWYDASKKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAAYYCARDP SSLTGSTGYYGMDVWGQGTTVTVSS 181 20A2.003 VL artificial SYELTQPPSVSVSPGQTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQD RKRPSGIPERFSGSNSGNTATLTISGTQAMDEADYYCQAFESSTEVFGGG TKLTVL 182 22D4.006 VH artificial EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSG INWNGGRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREF NNFESNWFDPWGQGTLVTVSS 183 22D4.006 VL artificial SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISED AKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFG GGTKLTVL 184 22D4.017 VH artificial EVQLVESGGSVVRPGGSLRLSCAASGFTVDDYSMSWVRQVPGKGLEWVSG INWNAGRTRYADAVKGRFTISRDSAKNSLYLQMNSLRAEDTALYYCAREF NNFESNWFDPWGQGTLVTVSS 185 22D4.017 VL artificial SYELTQPPSVSVSPGQTARITCSGDALPKKYAYWYQQKPGQAPVLVISED AKRPSGIPERFSGSSSGTMATLTISGAQVEDEADYYCYSTDASGNHRVFG GGTKLTVL 186 20A2 heavy chain artificial MDMRVPAQLLGLLLLWLRGARCQVQLVESGGGVVQPGRSLRLSCAASGFT FSNYGMHWVRQAPGKGLEWVALIWYDGSKKYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAAYYCAR DPSSLTGSTGYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNVNHKPSNTK VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLH QDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK 187 20A2 light chain artificial MAWALLLLTLLTQGTGSWASYELTQPPSVSVSPGQTASITCSGDKLGDKY ACWYQQKPGQSPVLVIYQDRKRPSGIPERFSGSNSGNTATLTISGTQAMD EADYYCQAWDSSTEVFGGGT KLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKAD SSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST VEKTVAPTECS 188 20C1 heavy chain artificial MDMRVPAQLLGLLLLWLRGARCEVQLLESGGGLVQPGGALRLSCAASGFT FSSYDMSWVRQAPGKGLEWVSLISGGGSNTYYADSVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYFCAS PSGHYFYAMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK 189 20C1 light chain artificial MDMRVPAQLLGLLLLWLRGARCDIQMTQSPSSVSASVGDRVTITCRASQG ISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFGGSGSGTDFTFTISSL QPEDFATYYCQQADSFPHTF GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 190 22D4 heavy chain artificial MDMRVPAQLLGLLLLWLRGARCEVQLVESGGSVVRPGGSLRLSCAASGFT VDDYSMSWVRQVPGKGLEWVSGINWNGGRTRYADSVKGRFTISRDSAKNS LYLQMNSLRAEDTALYYCAR EFNNFESNWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKK VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHODWL NGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK 191 22D4 light chain artificial MAWALLLLTLLTQGTGSWASYELTQPPSVSVSPGQTARITCSGDALPKKY AYWYQQKSGQAPVLVISEDSKRPSGIPERFSGSSSGTMATLTISGAQVED EADYYCYSTDSSGNHRVFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWK ADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEG STVEKTVAPTECS 192 20C1.006 artificial MDMRVPAQLLGLLLLWLRGARCEVQLLESGGGLVQPGGSLRLSCAASGFT heavy chain FSSYDMSWVRQAPGKGLEWVSLISGGGSNTYYAESVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYFCAS PSGHYFYAMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK 193 20C1.006 artificial MDMRVPAQLLGLLLLWLRGARCDIQMTQSPSSVSASVGDRVTITCRASQG light chain ISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQAESFPHTF GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 194 20C1.009 artificial MDMRVPAQLLGLLLLWLRGARCEVQLLESGGGLVQPGGSLRLSCAASGFT heavy chain FSSYDMSWVRQAPGKGLEWVSLISGGGSQTYYAESVKGRFTISRDNSKNT LYLQMNSLRAEDTAVYFCAS PSGHYFYAMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT QTYICNVNHKPSNTKVDKKV EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKT ISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNG QPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNH YTQKSLSLSPGK 195 20C1.009 artificial MDMRVPAQLLGLLLLWLRGARCDIQMTQSPSSVSASVGDRVTITCRASQG light chain ISNWLAWYQQKPGKAPKLLIFAASSLQSGVPSRFSGSGSGTDFTLTISSL QPEDFATYYCQQAESFPHTF GGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQW KVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTH QGLSSPVTKSFNRGEC 196 20A2.003 artificial MDMRVPAQLLGLLLLWLRGARCQVQLVESGGGVVQPGRSLRLSCAASGFT heavy chain FSNYGMHWVRQAPGKGLEWVALIWYDASKKYYAESVKGRFTISRDNSKNT LYLQMNSLRAEDTAAYYCAR DPSSLTGSTGYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTA ALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPS SSLGTQTYICNVNHKPSNTK VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLH QDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK 197 20A2.003 artificial MAWALLLLTLLTQGTGSWASYELTQPPSVSVSPGQTASITCSGDKLGDKY light chain ASWYQQKPGQSPVLVIYQDRKRPSGIPERFSGSNSGNTATLTISGTQAMD EADYYCQAFESSTEVFGGGT KLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKAD SSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGST VEKTVAPTECS 198 22D4.006 artificial MDMRVPAQLLGLLLLWLRGARCEVQLVESGGSVVRPGGSLRLSCAASGFT heavy chain VDDYSMSWVRQVPGKGLEWVSGINWNGGRTRYADAVKGRFTISRDSAKNS LYLQMNSLRAEDTALYYCAR EFNNFESNWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKK VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHODWL NGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK 199 22D4.006 artificial MAWALLLLTLLTQGTGSWASYELTQPPSVSVSPGQTARITCSGDALPKKY light chain AYWYQQKPGQAPVLVISEDAKRPSGIPERFSGSSSGTMATLTISGAQVED EADYYCYSTDASGNHRVFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWK ADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEG STVEKTVAPTECS 200 22D4.017 artificial MDMRVPAQLLGLLLLWLRGARCEVQLVESGGSVVRPGGSLRLSCAASGFT heavy chain VDDYSMSWVRQVPGKGLEWVSGINWNAGRTRYADAVKGRFTISRDSAKNS LYLQMNSLRAEDTALYYCAR EFNNFESNWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGC LVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLG TQTYICNVNHKPSNTKVDKK VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEK TISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESN GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN HYTQKSLSLSPGK 201 22D4.017 artificial MAWALLLLTLLTQGTGSWASYELTQPPSVSVSPGQTARITCSGDALPKKY light chain AYWYQQKPGQAPVLVISEDAKRPSGIPERFSGSSSGTMATLTISGAQVED EADYYCYSTDASGNHRVFGG GTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWK ADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEG STVEKTVAPTECS 202 linker 1 artificial GGGG 203 linker 2 artificial GGGGS 204 linker 3 artificial GGGGQ 205 linker 4 artificial SGGGGS 206 linker 5 artificial PGGGGS 207 linker 6 artificial PGGDGS 208 linker 7 artificial GGGGSGGGS 209 linker 8 = (G.sub.4S).sub.2 artificial GGGGSGGGGS linker 210 linker 9 = (6.sub.4S).sub.3 artificial GGGGSGGGGSGGGGS linker 211 (G.sub.4S).sub.4 linker artificial GGGGSGGGGSGGGGSGGGGS 212 (G.sub.4S).sub.5 linker artificial GGGGSGGGGSGGGGSGGGGSGGGGS 213 (G.sub.4S).sub.6 linker artificial GGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 214 (G.sub.4S).sub.7 linker artificial GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 215 (G.sub.4S).sub.8 linker artificial GGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGS 216 Ab156 artificial RDWDFDVFGGGTPVGG 217 linear FcRn BP artificial QRFVTGHFGGLXPANG 218 linear FcRn BP-Y artificial QRFVTGHFGGLYPANG 219 linear FcRn BP-H artificial QRFVTGHFGGLHPANG 220 core FcRn BP-H artificial TGHFGGLHP 221 cyclic FcRn BP-H artificial QRFCTGHFGGLHPCNG 222 HALB human DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 223 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 1 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 224 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 2 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 225 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 3 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL 226 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 4 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALGVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 227 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 5 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 228 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 6 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPHLVAASQAALGL 229 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 7 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL 230 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 8 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL 231 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFA variant 9 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL 232 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 10 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 233 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 11 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 234 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 12 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 235 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 13 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL 236 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 14 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALGVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 237 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 15 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 238 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 16 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPHLVAASQAALGL 239 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 17 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL 240 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 18 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL 241 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQSPFEDHVKLVNEVTEFA variant 19 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL 242 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 20 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 243 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 21 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAGTFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAAMDD FAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL 244 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 22 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 245 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 23 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL 246 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 24 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALGVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 247 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 25 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASQAALGL 248 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 26 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPHLVAASQAALGL 249 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 27 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPHLVAASKAALGL 250 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 28 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDK FAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL 251 HALB artificial DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQAPFEDHVKLVNEVTEFA variant 29 KTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNE CFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFY APELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKC ASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDL LECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPA DLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLA KTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGE YKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAE DYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALDVDETYVPK EFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDD FAAFVEKCCKADDKETCFAEEGPKLVAASKAALGL 252 Cross body 1 HC artificial ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMTSRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 253 Cross body 1 LC artificial GQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL NGKEYKCKVSNKALPAPTEKTTSKAKGQPREPQVYTLPPSRKEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 254 Cross body 2 HC artificial ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVEP KSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMTSRTPEVTCVVVDVS HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK 255 Cross body 2 LC artificial GQPKAAPSVTLFPPSSEELQANKATLVCLTSDFYPGAVTVAWKADSSPVK AGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTV APTECSEPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMTSRTPEV TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL HQDWLNGKEYKCKVSNKALPAPTEKTTSKAKGQPREPQVYTLPPSRKEMT KNQVSLTCLVKGFYPSDTAVEWESNGQPENNYKTTPPVLKSDGSFFLYSK LTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 256 Hetero-Fc binder Fc artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMTSRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSLTCLVK GFYPSDTAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 257 Hetero-Fc partner artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMTSRTPEVTCVVVDVSHED Fc PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDTAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 258 Maxi-body 1 target artificial EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD Fc VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 259 Maxi-body 1 CD3 Fc artificial EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 260 Maxi-body 2 target artificial EPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD Fc VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRKEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLKSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 261 Maxi-body 2 CD3 Fc artificial EPKSSDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 262 Mono Fc artificial APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVD GVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPA PIEKTISKAKGQPREPQVTTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE WESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK 263 Fc monomer-1 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED +c/-g PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 264 Fc monomer-2 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED +c/-g/delGK PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP 265 Fc monomer-3 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED -c/+g PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 266 Fc monomer-4 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED -c/+g/delGK PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP 267 Fc monomer-5 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED -c/-g PEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 268 Fc monomer-6 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED -c/-g/delGK PEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP 269 Fc monomer-7 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED +c/+g PEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK 270 Fc monomer-8 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED +c/+g/delGK PEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSP 271 scFc-1 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 272 SCFc-2 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSP 273 SCFC-3 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GEYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 274 ScFc-4 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSP 275 SCFc-5 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 276 scFc-6 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTOKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSP 277 scFc-7 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 278 scFc-8 artificial DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYNSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSP 279 5x his-tag artificial HHHHH 280 6x his-tag artificial HHHHHH 281 CL-1 x I2C bispecific QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGW molecule INPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDR ITVAGTYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS VSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPS RFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 282 CL-2 x I2C bispecific QVQMVQSGAEVKKHGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGW molecule INPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDR ITVAGTYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTOSPSS VSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPS RFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 283 CL-1 x I2C-6His bispecific QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGW molecule-his INPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDR tag ITVAGTYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS VSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPS RFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLOMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VLHHHHHH 284 CL-2 x I2C-6His bispecific QVQMVQSGAEVKKHGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGW molecule- INPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDR his tag ITVAGTYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS VSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPS RFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VLHHHHHH 285 AU1 epitope artificial DTYRYI 286 AU5 epitope artificial TDFYLK 287 T-7 tag artificial MASMTGGQQMG 288 V-5 tag artificial GKPIPNPLLGLDST 289 B-tag artificial QYPALT 290 E2 epitope artificial SSTSSDFRDR 291 FLAG tag artificial DYKDDDK 292 Glu-Glu tag 1 artificial EYMPME 293 Glu-Glu tag 2 artificial EFMPME 294 Histidine affinity artificial KDHL1HNVHKEFHAHAHNK tag 295 HSV epitope artificial QPELAPED 296 KT3 epitope artificial KPPTPPPEPET 297 Myc epitope artificial CEQKLISEEDL 298 7x his-tag artificial HHHHHHH 299 8x his-tag artificial HHHHHHHH 300 S1 tag artificial NANNPDWDF 301 S-tag artificial KETAAAKFERQHMDS 302 Strep-tag 1 artificial WSHPQFEK 303 Strep-tag 2 artificial AWAHPQPGG 304 Universal tag artificial HTTPHH 305 VSV-G artificial YTDIEMNRLGK 306 Protein C artificial EDQVDPRLIDGK 307 CD19XCD3 BISPECIFIC artificial DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKL SINGLE CHAIN LIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPW ANTIBODY TFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKA SGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADE SSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS GGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGL EWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYY CARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSP AIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVP YRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK 308 VH ANTI CD19 artificial QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQ IWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRE TTTVGRYYYAMDYWGQGTTVTVSS 309 VL ANTI CD19 artificial DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKL LIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPW TEGGGTKLEIK 310 CD19 CDR-H1 artificial SYWMN 311 CD19 CDR-H1 artificial GYAFSSYWMN 312 CD19 CDR-H2 artificial QIWPGDGDTNYNGKFKG 313 CD19 CDR-H3 artificial RETTTVGRYYYAMDY 314 CD19 CDR-L1 artificial KASQSVDYDGDSYLN 315 CD19 CDR-L2 artificial DASNLVS 316 CD19 CDR-L3 artificial QQSTEDPWT 317 CD33 CDR-L1 artificial KSSQSVLDSSTNKNSLA 318 CD33 CDR-L2 artificial WASTRES 319 CD33 CDR-L3 artificial QQSAHFPIT 320 CD33 CDR-L1 artificial KSSQSVLDSSKNKNSLA 321 CD33 CDR-L2 artificial WASTRE 322 CD33 CDR-L1 artificial KSSQSVLDSSNNKNSLA 323 CD33 CDR-H1 ARTIFICIAL NYGMN 324 CD33 CDR-H2 artificial WINTYTGEPTYADKFQG 325 CD33 CDR-H3 artificial WSWSDGYYVYFDY 326 CD33 CDR-H2 artificial WINTYTGEPTYADDFKG 327 CD33 CDR-H2 artificial WINTYTGETNYADKFQG 328 CD33VL REGION artificial DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPP KLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSPQPEDSATYYCQQSAHF PITFGQGTRLEIK 329 CD33VL REGION artificial DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSKNKNSLAWYQQKPGQPP KLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSLQPEDSATYYCQQSAHF PITFGQGTRLEIK 330 CD33VL REGION artificial DIVMTQSPDSMTVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPP KLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSLQPEDSATYYCQQSAHF PITFGQGTRLDIK 331 CD33VL REGION artificial DIVMTQSPDSLSVSLGERTTINCKSSQSVLDSSTNKNSLAWYQQKPGQPP KLLLSWASTRESGIPDRFSGSGSGTDFTLTIDSLQPEDSATYYCQQSAHF PITFGQGTRLEIK 332 CD33VL REGION artificial DIVMTQSPDSLTVSLGERTTINCKSSQSVLDSSNNKNSLAWYQQKPGQPP KLLLSWASTRESGIPDRFSGSGSGTDFTLTIDGLQPEDSATYYCQQSAHF PITFGQGTRLEIK 333 CD33VH REGION artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGW INTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLGGDDTAVYYCARWS WSDGYYVYFDYWGQGTSVTVSS 334 CD33VH artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGW INTYTGEPTYADDFKGRVTMSSDTSTSTAYLEINSLRSDDTAIYYCARWS WSDGYYVYFDYWGQGTTVTVSS 335 CD33VH artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGW INTYTGEPTYADDFKGRVTMTTDTSTSTAYMEIRNLRNDDTAVYYCARWS WSDGYYVYFDYWGQGTTVTVSS 336 CD33VH artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGW INTYTGEPTYADDFKGRVTMTTDTSTSTAYMEIRNLRNDDTAVYYCARWS WSDGYYVYFDYWGQGTTVTVSS 337 CD33VH artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLKWMGW INTYTGEPTYADDFKGRVTMTSDTSTSTAYMEISSLRSDDTAVYYCARWS WSDGYYVYFDYWGQGTTVTVSS 338 CD33VH artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGW INTYTGETNYADKFQGRVTFTSDTSTSTAYMELRNLKSDDTAVYYCARWS WSDGYYVYFDYWGQGTTVTVSS 339 CD33VH artificial QVQLVQSGAEVKKPGESVKVSCKASGYTFTNYGMNWVKQAPGQGLEWMGW INTYTGEPTYADKFQGRVTMTTDTSTSTAYMEIRNLRSDDTAVYYCARWS WSDGYYVYFDYWGQGTTVTVSS 340 CD33 UNIPROT ENTRY human MPLLLLLPLLWAGALAMDPNFWLQVQESVTVQEGLCVLVPCTFFHPIPYY P20138 DKNSPVHGYWFREGAIISRDSPVATNKLDQEVQEETQGRFRLLGDPSRNN CSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIP GTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIIT PRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTYVPQNPTTGIFPGDGSGK QETRAGVVHGAIGGAGVTALLALCLCLIFFIVKTHRRKAARTAVGRNDTH PTTGSASPKHQKKSKLHGPTETSSCSGAAPTVEMDEELHYASLNFHGMNP SKDTSTEYSEVRTQ 341 Flt3 VH-CDR1 artificial NARMGVS 342 Flt3 VH-CDR2 artificial HIFSNAEKSYRTSLKS 343 Flt3 VH-CDR3 artificial IPGYGGNGDYHYYGMDV 344 Flt3 VL-CDR1 artificial RASQGIRNDLG 345 Flt3 VL-CDR2 artificial ASSTLQS 346 Flt3 VL-CDR3 artificial LQHNNFPWT 347 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLINARMGVSWIRQPPGKALEWL AHIFSNAEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PGYGGNGDYHYYGMDVWGQGTTVTVSS 348 Flt3 VL region artificial DIQMTQSPSSLSASLGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA SSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNFPWTFGQ GTKVEIK 349 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLINARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNAEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PGYGGNGDYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP polypeptide SSLSASLGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYASSTLQSGV PSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNFPWTFGQGTKVEIK 350 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLINARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNAEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PGYGGNGDYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASLGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYASSTLQSGV PSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNFPWTFGQGTKVEIKS GGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAV YYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVT QEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK LTVL 351 Flt3 VH-CDR1 artificial NARMGVS 352 Flt3 VH-CDR2 artificial HIFSNDEKTYSTSLKS 353 Flt3 VH-CDR3 artificial IPYYGSGSHNYGMDV 354 Flt3 VL-CDR1 artificial RASQDIRNDFG 355 Flt3 VL-CDR2 artificial AASTLQS 356 Flt3 VL-CDR3 artificial LQYNTYPWT 357 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMGVSWIRQPPGKALEWL AHIFSNDEKTYSTSLKSRLTISRDTSKGQVVLTMTKMDPVDTATYYCARI PYYGSGSHNYGMDVWGQGTTVTVSS 358 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRNDFGWYQQKPGKAPQRLLYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQYNTYPWTFGQ GTKVEIK 359 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKTYSTSLKSRLTISRDTSKGQVVLTMTKMDPVDTATYYCARI comprises a PYYGSGSHNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS polypeptide LSASVGDRVTITCRASQDIRNDFGWYQQKPGKAPQRLLYAASTLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQYNTYPWTFGQGTKVEIK 360 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKTYSTSLKSRLTISRDTSKGQVVLTMTKMDPVDTATYYCARI FLT3 PYYGSGSHNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS LSASVGDRVTITCRASQDIRNDFGWYQQKPGKAPQRLLYAASTLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQYNTYPWTFGQGTKVEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 361 Flt3 VH-CDR1 artificial NARMAVS 362 Flt3 VH-CDR2 artificial HIFSNGEKSYSTSLKS 363 Flt3 VH-CDR3 artificial IVGYSDWLLPFDH 364 Flt3 VL-CDR1 artificial RASQNINRFLN 365 Flt3 VL-CDR2 artificial AASSLQS 366 Flt3 VL-CDR3 artificial LQHNSYPWT 367 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSNARMAVSWIRQPPGKALEWL AHIFSNGEKSYSTSLKSRLTISKDTSKTQVVLTMTNTDPVDTATYFCARI VGYSDWLLPFDHWGQGIMVTVSS 368 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQNINRFLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPWTFGQ GTKVDIK 369 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSNARMAVSWIRQPPGKALEWL binds to FLT3 AHIFSNGEKSYSTSLKSRLTISKDTSKTQVVLTMTNTDPVDTATYFCARI comprises a VGYSDWLLPFDHWGQGIMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLS polypeptide ASVGDRVTITCRASQNINRFLNWYQQKPGKAPKLLIYAASSLQSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVDIK 370 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSNARMAVSWIRQPPGKALEWL binding to CD3 and AHIFSNGEKSYSTSLKSRLTISKDTSKTQVVLTMTNTDPVDTATYFCARI FLT3 VGYSDWLLPFDHWGQGIMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLS ASVGDRVTITCRASQNINRFLNWYQQKPGKAPKLLIYAASSLQSGVPSRF SGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPWTFGQGTKVDIKSGGGG SEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVA RIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCV RHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPS LTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPG TPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 371 Flt3 VH-CDR1 artificial NAKMGVS 372 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 373 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 374 Flt3 VL-CDR1 artificial RASQDIRDDLG 375 Flt3 VL-CDR2 artificial GASTLQS 376 Flt3 VL-CDR3 artificial LQHNSYPLT 377 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNAKMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 378 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYG ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVDIK 379 second domain which artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNAKMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIK 380 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNAKMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 381 Flt3 VH-CDR1 artificial NARMGVS 382 Flt3 VH-CDR2 artificial HIFWNDEKSYSTSLKS 383 Flt3 VH-CDR3 artificial IPYYGSGSYNYGMDV 384 Flt3 VL-CDR1 artificial RASQGIRNDLG 385 Flt3 VL-CDR2 artificial AASSLQS 386 Flt3 VL-CDR3 artificial LQHNTYPLT 387 Flt3 VH region artificial QVTLKESGPMLVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKALEWL AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PYYGSGSYNYGMDVWGQGTTVTVSS 388 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPLTFGG GTKVDIK 389 second domain which artificial QVTLKESGPMLVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PYYGSGSYNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS polypeptide LSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPLTFGGGTKVDIK 390 Antibody construct artificial QVTLKESGPMLVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PYYGSGSYNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS LSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPLTFGGGTKVDIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 391 Flt3 VH-CDR1 artificial NARMAVS 392 Flt3 VH-CDR2 artificial HIFSNDEKSYSPSLKS 393 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 394 Flt3 VL-CDR1 artificial RASQGIRNDLG 395 Flt3 VL-CDR2 artificial AASVLQS 396 Flt3 VL-CDR3 artificial LQHNSYPLT 397 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL AHIFSNDEKSYSPSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI VGYGTGWYGFFDYWGQGILVTVSS 398 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWFQQKPGKAPKRLIYA ASVLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVDIK 399 second domain which artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binds to FLT3 AHIFSNDEKSYSPSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI comprises a VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWFQQKPGKAPKRLIYAASVLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIK 400 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binding to CD3 and AHIFSNDEKSYSPSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWFQQKPGKAPKRLIYAASVLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 401 Flt3 VH-CDR1 artificial NARMGVS 402 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKN 403 Flt3 VH-CDR3 artificial IVGYGTGWFGYFDY 404 Flt3 VL-CDR1 artificial RASQDIRTDLA 405 Flt3 VL-CDR2 artificial AASSLQS 406 Flt3 VL-CDR3 artificial LQHNRYPLT 407 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI VGYGTGWFGYFDYWGQGTQVTVSS 408 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRTDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNRYPLTFGG GTKVDIK 409 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI comprises a VGYGTGWFGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRTDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNRYPLTFGGGTKVDIK 410 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI FLT3 VGYGTGWFGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRTDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNRYPLTFGGGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 411 Flt3 VH-CDR1 artificial YARMGVS 412 Flt3 VH-CDR2 artificial QIFSNDEKSYSTSLKS 413 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 414 Flt3 VL-CDR1 artificial RASQGIRNDLG 415 Flt3 VL-CDR2 artificial AASSLQS 416 Flt3 VL-CDR3 artificial LQHNSYPLT 417 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSYARMGVSWIRQPPGKALEWL AQIFSNDEKSYSTSLKSRLTISKGTSNSQVVLTMTNMDPEDTATYYCARI VGYGTGWYGFFDYWGQGILVTVSS 418 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVDIK 419 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSYARMGVSWIRQPPGKALEWL binds to FLT3 AQIFSNDEKSYSTSLKSRLTISKGTSNSQVVLTMTNMDPEDTATYYCARI comprises a VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIK 420 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSYARMGVSWIRQPPGKALEWL binding to CD3 and AQIFSNDEKSYSTSLKSRLTISKGTSNSQVVLTMTNMDPEDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 421 Flt3 VH-CDR1 artificial NARMGVS 422 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 423 Flt3 VH-CDR3 artificial IPGYGGNFYYHYYGMDV 424 Flt3 VL-CDR1 artificial RASQGIRNDLA 425 Flt3 VL-CDR2 artificial AASTVQS 426 Flt3 VL-CDR3 artificial LQHNSFPWT 427 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PGYGGNFYYHYYGMDVWGQGTTVTVSS 428 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYA ASTVQSGVPSRFSGSGSGTEFALTISSLQPEDFATYYCLQHNSFPWTFGQ GTKVDIK 429 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PGYGGNFYYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP polypeptide SSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASTVQSGV PSRFSGSGSGTEFALTISSLQPEDFATYYCLQHNSFPWTFGQGTKVDIK 430 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PGYGGNFYYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASTVQSGV PSRFSGSGSGTEFALTISSLQPEDFATYYCLQHNSFPWTFGQGTKVDIKS GGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAV YYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVT QEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK LTVL 431 Flt3 VH-CDR1 artificial NARMGVS 432 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 433 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 434 Flt3 VL-CDR1 artificial RASQDIRDDLG 435 Flt3 VL-CDR2 artificial GASTLQS 436 Flt3 VL-CDR3 artificial LQHNSYPLT 437 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 438 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYG ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVDIK 439 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIK 440 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 441 Flt3 VH-CDR1 artificial NAKMGVS 442 Flt3 VH-CDR2 artificial QIFSNGEKSYSTSLKS 443 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 444 Flt3 VL-CDR1 artificial RASQGIRNDLG 445 Flt3 VL-CDR2 artificial GASTLQS 446 Flt3 VL-CDR3 artificial LQHNSYPLT 447 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTLSGFSLNNAKMGVSWIRQPPGKALEWL AQIFSNGEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCSRI VGYGSGWYGYFDYWGQGTLVTVSS 448 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYG ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 449 second domain which artificial QVTLKESGPVLVKPTETLTLTCTLSGFSLNNAKMGVSWIRQPPGKALEWL binds to FLT3 AQIFSNGEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCSRI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 450 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTLSGFSLNNAKMGVSWIRQPPGKALEWL binding to CD3 and AQIFSNGEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCSRI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 451 Flt3 VH-CDR1 artificial NARMGVS 452 Flt3 VH-CDR2 artificial NIFSNDEKSYSTSLKS 453 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 454 Flt3 VL-CDR1 artificial RASQGIRNDLG 455 Flt3 VL-CDR2 artificial AASSLQS 456 Flt3 VL-CDR3 artificial LQHNSYPLT 457 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNMDPEDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 458 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPQRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 459 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNMDPEDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPQRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 460 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNMDPEDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPQRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 461 Flt3 VH-CDR1 artificial NARMGVS 462 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKN 463 Flt3 VH-CDR3 artificial IVGYGSGWYGFFDY 464 Flt3 VL-CDR1 artificial RASQGIRNDLG 465 Flt3 VL-CDR2 artificial AASTLQS 466 Flt3 VL-CDR3 artificial LQHNSYPLT 467 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI VGYGSGWYGFFDYWGQGTLVTVSS 468 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 469 second domain which artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI comprises a VGYGSGWYGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 470 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI FLT3 VGYGSGWYGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 471 Flt3 VH-CDR1 artificial NARMAVS 472 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 473 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 474 Flt3 VL-CDR1 artificial RASQDIRNDLG 475 Flt3 VL-CDR2 artificial AASTLQS 476 Flt3 VL-CDR3 artificial LQHNSYPLT 477 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 478 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 479 second domain which artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 480 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 481 Flt3 VH-CDR1 artificial NARMAVS 482 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 483 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 484 Flt3 VL-CDR1 artificial RASQDIGNDLG 485 Flt3 VL-CDR2 artificial AASSLQS 486 Flt3 VL-CDR3 artificial LQHNSYPLT 487 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 488 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIGNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 489 second domain which artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIGNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 490 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIGNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 491 Flt3 VH-CDR1 artificial NARMAVS 492 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 493 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 494 Flt3 VL-CDR1 artificial RASQDIRYDLA 495 Flt3 VL-CDR2 artificial AASSLQS 496 Flt3 VL-CDR3 artificial LQHNFYPLT 497 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMAVSWIRQPPGKTLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 498 Flt3 VL region artificial DIQMTQSPSSVSASVGDRVTITCRASQDIRYDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNFYPLTFGG GTKVEIK 499 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMAVSWIRQPPGKTLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSV polypeptide SASVGDRVTITCRASQDIRYDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNFYPLTFGGGTKVEIK 500 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMAVSWIRQPPGKTLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSV SASVGDRVTITCRASQDIRYDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNFYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 501 Flt3 VH-CDR1 artificial NARMGVS 502 Flt3 VH-CDR2 artificial NIFSNDEKSYSTSLKS 503 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 504 Flt3 VL-CDR1 artificial RASQDIRNDLG 505 Flt3 VL-CDR2 artificial ATSIRQS 506 Flt3 VL-CDR3 artificial LQHNSFPLT 507 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNVNPVDTGTYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 508 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYA TSIRQSGVPSRFTGSGSGTEFTLTISGLQPEDFATYFCLQHNSFPLTFGG GTKVEIK 509 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNVNPVDTGTYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYATSIRQSGVPSR FTGSGSGTEFTLTISGLQPEDFATYFCLQHNSFPLTFGGGTKVEIK 510 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNVNPVDTGTYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYATSIRQSGVPSR FTGSGSGTEFTLTISGLQPEDFATYFCLQHNSFPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 511 Flt3 VH-CDR1 artificial NARMGVS 512 Flt3 VH-CDR2 artificial HIFSNDEKSFSTSLKN 513 Flt3 VH-CDR3 artificial MVGYGSGWYAYFDY 514 Flt3 VL-CDR1 artificial RASQSISSYLN 515 Flt3 VL-CDR2 artificial AASSLQS 516 Flt3 VL-CDR3 artificial LQHNSYPLT 517 Flt3 VH region artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL AHIFSNDEKSFSTSLKNRLTISKDTSKSQVVLTMTNMDPVDTATYYCARM VGYGSGWYAYFDYWGQGTQVIVSS 518 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 519 second domain which artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSFSTSLKNRLTISKDTSKSQVVLTMTNMDPVDTATYYCARM comprises a VGYGSGWYAYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 520 Antibody construct artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSFSTSLKNRLTISKDTSKSQVVLTMTNMDPVDTATYYCARM FLT3 VGYGSGWYAYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 521 Flt3 VH-CDR1 artificial YARMGVS 522 Flt3 VH-CDR2 artificial QIFSNDEKSYSTSLKS 523 Flt3 VH-CDR3 artificial IVGYGTGWYGYFDY 524 Flt3 VL-CDR1 artificial RASQDIGDDLG 525 Flt3 VL-CDR2 artificial AASTLQS 526 Flt3 VL-CDR3 artificial LQHNSYPLT 527 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSYARMGVSWIRQPPGKALEWL AQIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI VGYGTGWYGYFDYWGQGTQVTVSS 528 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIGDDLGWYQQKPGKAPKRLIYA ASTLQSGVPFRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 529 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSYARMGVSWIRQPPGKALEWL binds to FLT3 AQIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI comprises a VGYGTGWYGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIGDDLGWYQQKPGKAPKRLIYAASTLQSGVPFR FSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 530 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSYARMGVSWIRQPPGKALEWL binding to CD3 and AQIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI FLT3 VGYGTGWYGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIGDDLGWYQQKPGKAPKRLIYAASTLQSGVPFR FSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 531 Flt3 VH-CDR1 artificial NARMAVS 532 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 533 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 534 Flt3 VL-CDR1 artificial RASQGIRNDLA 535 Flt3 VL-CDR2 artificial AASSLQS 536 Flt3 VL-CDR3 artificial LQHNSYPLT 537 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI VGYGTGWYGFFDYWGQGILVTVSS 538 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 539 second domain which artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI comprises a VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 540 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKTLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 541 Flt3 VH-CDR1 artificial NARMGVS 542 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 543 Flt3 VH-CDR3 artificial IPGYGGNFYYHYYGMDV 544 Flt3 VL-CDR1 artificial RTSRGIRNDLG 545 Flt3 VL-CDR2 artificial AASTLQS 546 Flt3 VL-CDR3 artificial LQHNNFPWT 547 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PGYGGNFYYHYYGMDVWGQGTTVTVSS 548 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSRGIRNDLGWYQQIPGRAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNFPWTFGQ GTKVEIK 549 second domain which artificial QVTLKESGPALVKPTETLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PGYGGNFYYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP polypeptide SSLSASVGDRVTITCRTSRGIRNDLGWYQQIPGRAPKRLIYAASTLQSGV PSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNFPWTFGQGTKVEIK 550 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PGYGGNFYYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRTSRGIRNDLGWYQQIPGRAPKRLIYAASTLQSGV PSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNNFPWTFGQGTKVEIKS GGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAV YYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVT QEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK LTVL 551 Flt3 VH-CDR1 artificial NARMGVS 552 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 553 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 554 Flt3 VL-CDR1 artificial RASQGISNYLA 555 Flt3 VL-CDR2 artificial AASTLQS 556 Flt3 VL-CDR3 artificial LQHNTYPWT 557 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 558 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPWTFGQ GTKVEIK 559 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGISNYLAWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPWTFGQGTKVEIK 560 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGISNYLAWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPWTFGQGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 561 Flt3 VH-CDR1 artificial NARMGVS 562 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 563 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 564 Flt3 VL-CDR1 artificial RASQDIGYDLG 565 Flt3 VL-CDR2 artificial AASTLQS 566 Flt3 VL-CDR3 artificial LQHNSFPWT 567 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 568 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIGYDLGWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLIISSLQPEDFATYYCLQHNSFPWTFGQ GTKVEIK 569 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIGYDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLIISSLQPEDFATYYCLQHNSFPWTFGQGTKVEIK 570 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIGYDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLIISSLQPEDFATYYCLQHNSFPWTFGQGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 571 Flt3 VH-CDR1 artificial NVRMGVS 572 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 573 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 574 Flt3 VL-CDR1 artificial RASQDIRDDLV 575 Flt3 VL-CDR2 artificial AASTLQS 576 Flt3 VL-CDR3 artificial LQHHSYPWT 577 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLILTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 578 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRDDLVWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHHSYPWTFGQ GTKVEIK 579 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLILTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRDDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHHSYPWTFGQGTKVEIK 580 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLILTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRDDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHHSYPWTFGQGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 581 Flt3 VH-CDR1 artificial NARMGVS 582 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 583 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 584 Flt3 VL-CDR1 artificial RASQDIRDDLG 585 Flt3 VL-CDR2 artificial AASTLQS 586 Flt3 VL-CDR3 artificial LQHNSFPFT 587 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 588 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRDDLGWYQQKPGKAPKRLIYA ASTLQSGVPSRFTGGGSGTEFTLTISSLQPEDFATYYCLQHNSFPFTFGG GTKVEIK 589 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRDDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FTGGGSGTEFTLTISSLQPEDFATYYCLQHNSFPFTFGGGTKVEIK 590 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRDDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FTGGGSGTEFTLTISSLQPEDFATYYCLQHNSFPFTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 591 Flt3 VH-CDR1 artificial NARMGVS 592 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 593 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 594 Flt3 VL-CDR1 artificial RASQGIRNDLV 595 Flt3 VL-CDR2 artificial GTSTLQS 296 Flt3 VL-CDR3 artificial LQHNSYPLT 597 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 598 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYG TSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 599 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYGTSTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 600 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYGTSTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 601 Flt3 VH-CDR1 artificial NARMGVS 602 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 603 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 604 Flt3 VL-CDR1 artificial RTSQGIRNDLV 605 Flt3 VL-CDR2 artificial AASTLQS 606 Flt3 VL-CDR3 artificial LQHYSYPLT 607 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 608 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSQGIRNDLVWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCLQHYSYPLTFGG GTKVEIK 609 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRTSQGIRNDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCLQHYSYPLTFGGGTKVEIK 610 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRTSQGIRNDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCLQHYSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 611 Flt3 VH-CDR1 artificial NARMGVS 612 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 613 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 614 Flt3 VL-CDR1 artificial RASQGIGDDLG 615 Flt3 VL-CDR2 artificial ATSVLQS 616 Flt3 VL-CDR3 artificial LQHNSYPLT 617 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 618 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQIPGKAPKRLIYA TSVLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 619 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIGDDLGWYQQIPGKAPKRLIYATSVLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 620 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIGDDLGWYQQIPGKAPKRLIYATSVLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 621 Flt3 VH-CDR1 artificial NARMGVS 622 Flt3 VH-CDR2 artificial HIFSNDEKSYRTSLKS 623 Flt3 VH-CDR3 artificial IVGYGSGWYAYFDY 624 Flt3 VL-CDR1 artificial RASQGIRNDLG 625 Flt3 VL-CDR2 artificial AASSLQS 626 Flt3 VL-CDR3 artificial LQHNSYPLT 627 Flt3 VH region artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL AHIFSNDEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI VGYGSGWYAYFDYWGQGTLVTVSS 628 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 629 second domain which artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 630 Antibody construct artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 631 Flt3 VH-CDR1 artificial NARMGVS 632 Flt3 VH-CDR2 artificial LIYWNDDKRYSPSLKS 633 Flt3 VH-CDR3 artificial MVGYGSGWYAYFDY 634 Flt3 VL-CDR1 artificial RASQGIRNDLG 635 Flt3 VL-CDR2 artificial AASSLQS 636 Flt3 VL-CDR3 artificial LQHNSYPLT 637 Flt3 VH region artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL ALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARM VGYGSGWYAYFDYWGQGTLVTVSS 638 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 639 second domain which artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 ALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARM comprises a VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 640 Antibody construct artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and ALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARM FLT3 VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 641 Flt3 VH-CDR1 artificial NARMGVS 642 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 643 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 644 Flt3 VL-CDR1 artificial RTSQGIRNDLG 645 Flt3 VL-CDR2 artificial AASSLQS 646 Flt3 VL-CDR3 artificial LQHNSYPLT 647 Flt3 VH region artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI VGYGTGWYGFFDYWGQGILVTVSS 648 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 649 second domain which artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI comprises a VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRTSQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 650 Antibody construct artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRTSQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 651 Flt3 VH-CDR1 artificial NARMGVS 652 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 653 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 654 Flt3 VL-CDR1 artificial RASQGIRNDLV 655 Flt3 VL-CDR2 artificial AASTLQS 656 Flt3 VL-CDR3 artificial LQHYSYPLT 657 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 658 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFILTISSLQPEDFATYFCLQHYSYPLTFGG GTKLEIK 659 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFILTISSLQPEDFATYFCLQHYSYPLTFGGGTKLEIK 660 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFILTISSLQPEDFATYFCLQHYSYPLTFGGGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 661 Flt3 VH-CDR1 artificial NARMGVS 662 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 663 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 664 Flt3 VL-CDR1 artificial RASQGIGDDLG 665 Flt3 VL-CDR2 artificial ATSVLQS 666 Flt3 VL-CDR3 artificial LQHNSYPLT 667 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMGVSWIRQPPGKTLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 668 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIGDDLGWYQQIPGKAPKRLIYA TSVLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKLEIK 669 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMGVSWIRQPPGKTLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIGDDLGWYQQIPGKAPKRLIYATSVLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIK 670 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNARMGVSWIRQPPGKTLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKGQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIGDDLGWYQQIPGKAPKRLIYATSVLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 671 Flt3 VH-CDR1 artificial NARMGVS 672 Flt3 VH-CDR2 artificial HIFWNDEKSYSTSLKS 673 Flt3 VH-CDR3 artificial IPYYGSGSYNYGMDV 674 Flt3 VL-CDR1 artificial RASQGIRNDLG 675 Flt3 VL-CDR2 artificial AASSLQS 676 Flt3 VL-CDR3 artificial LQHNSYPLT 677 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKALEWL AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PYYGSGSYNYGMDVWGQGTTVTVSS 678 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKLEIK 679 second domain which artificial QVTLKESGPALVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PYYGSGSYNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS polypeptide LSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIK 680 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PYYGSGSYNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS LSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 681 Flt3 VH-CDR1 artificial NARMGVS 682 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKN 683 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 684 Flt3 VL-CDR1 artificial RASQDIRDDLV 685 Flt3 VL-CDR2 artificial GTSTLQS 686 Flt3 VL-CDR3 artificial LQHHSYPLT 687 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI VGYGTGWYGFFDYWGQGTQVTVSS 688 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRDDLVWYQQKPGKAPKRLIYG TSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHHSYPLTFGG GTKLEIK 689 second domain which artificial QVTLKESGPALVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI comprises a VGYGTGWYGFFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRDDLVWYQQKPGKAPKRLIYGTSTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHHSYPLTFGGGTKLEIK 690 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRDDLVWYQQKPGKAPKRLIYGTSTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHHSYPLTFGGGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 691 Flt3 VH-CDR1 artificial YARMGVS 692 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 693 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 694 Flt3 VL-CDR1 artificial RASQDIRNDLA 695 Flt3 VL-CDR2 artificial AASSLQS 696 Flt3 VL-CDR3 artificial LQHNSYPLT 697 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 698 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKLEIK 699 second domain which artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIK 700 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 701 Flt3 VH-CDR1 artificial NIKMGVS 702 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 703 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 704 Flt3 VL-CDR1 artificial RASQDISNYLA 705 Flt3 VL-CDR2 artificial AASSLQS 706 Flt3 VL-CDR3 artificial LQHNSFPLT 707 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNIKMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 708 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPLTFGG GTKLEIK 709 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNIKMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDISNYLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPLTFGGGTKLEIK 710 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNIKMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDISNYLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSFPLTFGGGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 711 Flt3 VH-CDR1 artificial NARMGVS 712 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 713 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 714 Flt3 VL-CDR1 artificial RASQGIRNDLG 715 Flt3 VL-CDR2 artificial AASSLQS 716 Flt3 VL-CDR3 artificial LQHNSYPLT 717 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTLVTVSS 718 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKLEIK 719 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIK 720 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 721 Flt3 VH-CDR1 artificial NARMGVS 722 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKN 723 Flt3 VH-CDR3 artificial IVGYGSGWYGFFDY 724 Flt3 VL-CDR1 artificial RASQGIRNDLG 725 Flt3 VL-CDR2 artificial AASTLQS 726 Flt3 VL-CDR3 artificial LQHNSYPLT 727 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI VGYGSGWYGFFDYWGQGTLVTVSS 728 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 729 second domain which artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI comprises a VGYGSGWYGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 730 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTLSGFSLNNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI FLT3 VGYGSGWYGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 731 Flt3 VH-CDR1 artificial NARMGVS 732 Flt3 VH-CDR2 artificial NIFSNDEKSYSTSLKS 733 Flt3 VH-CDR3 artificial IVGYGSGWYGYFDY 734 Flt3 VL-CDR1 artificial RASQDIRNDLG 735 Flt3 VL-CDR2 artificial ATSIRQS 736 Flt3 VL-CDR3 artificial LQHNSFPLT 737 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKCLEWL ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNVNPVDTGTYYCARI VGYGSGWYGYFDYWGQGTLVTVSS 738 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYA TSIRQSGVPSRFTGSGSGTEFTLTISGLQPEDFATYFCLQHNSFPLTFGC GTKVEIK 739 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKCLEWL binds to FLT3 ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNVNPVDTGTYYCARI comprises a VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYATSIRQSGVPSR FTGSGSGTEFTLTISGLQPEDFATYFCLQHNSFPLTFGCGTKVEIK 740 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKCLEWL binding to CD3 and ANIFSNDEKSYSTSLKSRLTISKGTSKSQVVLTMTNVNPVDTGTYYCARI FLT3 VGYGSGWYGYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRNDLGWYQQKPGKAPKRLIYATSIRQSGVPSR FTGSGSGTEFTLTISGLQPEDFATYFCLQHNSFPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 741 Flt3 VH-CDR1 artificial NARMGVS 742 Flt3 VH-CDR2 artificial HIFSNDEKSFSTSLKN 743 Flt3 VH-CDR3 artificial MVGYGSGWYAYFDY 744 Flt3 VL-CDR1 artificial RASQSISSYLN 745 Flt3 VL-CDR2 artificial AASSLQS 746 Flt3 VL-CDR3 artificial LQHNSYPLT 747 Flt3 VH region artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL AHIFSNDEKSFSTSLKNRLTISKDTSKSQVVLTMTNMDPVDTATYYCARM VGYGSGWYAYFDYWGQGTQVIVSS 748 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 749 second domain which artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSFSTSLKNRLTISKDTSKSQVVLTMTNMDPVDTATYYCARM comprises a VGYGSGWYAYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 750 Antibody construct artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSFSTSLKNRLTISKDTSKSQVVLTMTNMDPVDTATYYCARM FLT3 VGYGSGWYAYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSR FSGSGSGTDFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 751 Flt3 VH-CDR1 artificial NARMAVS 752 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 753 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 754 Flt3 VL-CDR1 artificial RASQGIRNDLA 755 Flt3 VL-CDR2 artificial AASSLQS 756 Flt3 VL-CDR3 artificial LQHNSYPLT 757 Flt3 VH region artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI VGYGTGWYGFFDYWGQGILVTVSS 758 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 759 second domain which artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI comprises a VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 760 Antibody construct artificial QVTLKESGPALVKPTETLTLTCTLSGFSLNNARMAVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 761 Flt3 VH-CDR1 artificial NARMGVS 762 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 763 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 764 Flt3 VL-CDR1 artificial RASQGIRNDLV 765 Flt3 VL-CDR2 artificial GTSTLQS 766 Flt3 VL-CDR3 artificial LQHNSYPLT 767 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 768 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYG TSTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 769 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYGTSTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 770 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLVWYQQKPGKAPKRLIYGTSTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 771 Flt3 VH-CDR1 artificial NARMGVS 772 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 773 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 774 Flt3 VL-CDR1 artificial RTSQGIRNDLV 775 Flt3 VL-CDR2 artificial AASTLQS 776 Flt3 VL-CDR3 artificial LQHYSYPLT 777 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 778 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSQGIRNDLVWYQQKPGKAPKRLIYA ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYFCLQHYSYPLTFGC GTKVEIK 779 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRTSQGIRNDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCLQHYSYPLTFGCGTKVEIK 780 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSFRNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRTSQGIRNDLVWYQQKPGKAPKRLIYAASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYFCLQHYSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 781 Flt3 VH-CDR1 artificial NARMGVS 782 Flt3 VH-CDR2 artificial HIFSNDEKSYRTSLKS 783 Flt3 VH-CDR3 artificial IVGYGSGWYAYFDY 784 Flt3 VL-CDR1 artificial RASQGIRNDLG 785 Flt3 VL-CDR2 artificial AASSLQS 786 Flt3 VL-CDR3 artificial LQHNSYPLT 787 Flt3 VH region artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI VGYGSGWYAYFDYWGQGTLVTVSS 788 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 789 second domain which artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 790 Antibody construct artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYRTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 791 Flt3 VH-CDR1 artificial NARMGVS 792 Flt3 VH-CDR2 artificial LIYWNDDKRYSPSLKS 793 Flt3 VH-CDR3 artificial MVGYGSGWYAYFDY 794 Flt3 VL-CDR1 artificial RASQGIRNDLG 795 Flt3 VL-CDR2 artificial AASSLQS 796 Flt3 VL-CDR3 artificial LQHNSYPLT 797 Flt3 VH region artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL ALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARM VGYGSGWYAYFDYWGQGTLVTVSS 798 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 799 second domain which artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binds to FLT3 ALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARM comprises a VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 800 Antibody construct artificial QVTLKESGPVLVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binding to CD3 and ALIYWNDDKRYSPSLKSRLTITKDTSKNQVVLTMTNMDPVDTATYYCARM FLT3 VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 801 Flt3 VH-CDR1 artificial NARMGVS 802 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 803 Flt3 VH-CDR3 artificial IVGYGTGWYGFFDY 804 Flt3 VL-CDR1 artificial RTSQGIRNDLG 805 Flt3 VL-CDR2 artificial AASSLQS 806 Flt3 VL-CDR3 artificial LQHNSYPLT 807 Flt3 VH region artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI VGYGTGWYGFFDYWGQGILVTVSS 808 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 809 second domain which artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI comprises a VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRTSQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 810 Antibody construct artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTDMDPEDTATYYCARI FLT3 VGYGTGWYGFFDYWGQGILVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRTSQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 811 Flt3 VH-CDR1 artificial NARMGVS 812 Flt3 VH-CDR2 artificial HIFWNDEKSYSTSLKS 813 Flt3 VH-CDR3 artificial IPYYGSGSYNYGMDV 814 Flt3 VL-CDR1 artificial RASQGIRNDLG 815 Flt3 VL-CDR2 artificial AASSLQS 816 Flt3 VL-CDR3 artificial LQHNTYPLT 817 Flt3 VH region artificial QVTLKESGPMLVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKCLEWL AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PYYGSGSYNYGMDVWGQGTTVTVSS 818 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPLTFGC GTKVDIK 819 second domain which artificial QVTLKESGPMLVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PYYGSGSYNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS polypeptide LSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPLTFGCGTKVDIK 820 Antibody construct artificial QVTLKESGPMLVKPTETLTLTCTFSGFSLRNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFWNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PYYGSGSYNYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS LSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPS RFSGSGSGTEFTLTISSLQPEDFATYYCLQHNTYPLTFGCGTKVDIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 821 Flt3 VH-CDR1 artificial NARMGVS 822 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKN 823 Flt3 VH-CDR3 artificial IVGYGTGWFGYFDY 824 Flt3 VL-CDR1 artificial RASQDIRTDLA 825 Flt3 VL-CDR2 artificial AASSLQS 826 Flt3 VL-CDR3 artificial LQHNRYPLT 827 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI VGYGTGWFGYFDYWGQGTQVTVSS 828 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRTDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNRYPLTFGC GTKVDIK 829 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI comprises a VGYGTGWFGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRTDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNRYPLTFGCGTKVDIK 830 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLNNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKNRLTISKDSSKTQVVLTMTNVDPVDTATYYCARI FLT3 VGYGTGWFGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRTDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNRYPLTFGCGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 831 Flt3 VH-CDR1 artificial NARMGVS 832 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 833 Flt3 VH-CDR3 artificial IPGYGGNFYYHYYGMDV 834 Flt3 VL-CDR1 artificial RASQGIRNDLA 835 Flt3 VL-CDR2 artificial AASTVQS 836 Flt3 VL-CDR3 artificial LQHNSFPWT 837 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI PGYGGNFYYHYYGMDVWGQGTTVTVSS 838 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYA ASTVQSGVPSRFSGSGSGTEFALTISSLQPEDFATYYCLQHNSFPWTFGC GTKVDIK 839 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI comprises a PGYGGNFYYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP polypeptide SSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASTVQSGV PSRFSGSGSGTEFALTISSLQPEDFATYYCLQHNSFPWTFGCGTKVDIK 840 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLSNARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARI FLT3 PGYGGNFYYHYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRASQGIRNDLAWYQQKPGKAPKRLIYAASTVQSGV PSRFSGSGSGTEFALTISSLQPEDFATYYCLQHNSFPWTFGCGTKVDIKS GGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAV YYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVT QEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK LTVL 841 Flt3 VH-CDR1 artificial NVRMGVS 842 Flt3 VH-CDR2 artificial HISSNDEKSYSTSLRS 843 Flt3 VH-CDR3 artificial MPGDSNTWRGFFDY 844 Flt3 VL-CDR1 artificial RTSQSVNNNLA 845 Flt3 VL-CDR2 artificial GASTRAT 846 Flt3 VL-CDR3 artificial LQHNSYPLT 847 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKCLEWL AHISSNDEKSYSTSLRSRLTISTDTSKSQVVLTMTNMDPVDTATYYCARM PGDSNTWRGFFDYWGQGTLVTVSS 848 Flt3 VL region artificial EIVMTQSPATLSVSPGERATLSCRTSQSVNNNLAWYQQKPGQAPRLLIYG ASTRATGIPARFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVEIK 849 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKCLEWL binds to FLT3 AHISSNDEKSYSTSLRSRLTISTDTSKSQVVLTMTNMDPVDTATYYCARM comprises a PGDSNTWRGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATL polypeptide SVSPGERATLSCRTSQSVNNNLAWYQQKPGQAPRLLIYGASTRATGIPAR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIK 850 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKCLEWL binding to CD3 and AHISSNDEKSYSTSLRSRLTISTDTSKSQVVLTMTNMDPVDTATYYCARM FLT3 PGDSNTWRGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATL SVSPGERATLSCRTSQSVNNNLAWYQQKPGQAPRLLIYGASTRATGIPAR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 851 Flt3 VH-CDR1 artificial YARMGVS 852 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 853 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 854 Flt3 VL-CDR1 artificial RASQDIRNDLA 855 Flt3 VL-CDR2 artificial AASSLQS 856 Flt3 VL-CDR3 artificial LQHNSYPLT 857 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKCLEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 858 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRNDLAWYQQKPGKAPKRLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKLEIK 859 second domain which artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKCLEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKLEIK 860 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKCLEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRNDLAWYQQKPGKAPKRLIYAASSLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 861 Flt3 VH-CDR1 artificial SYGMH 862 Flt3 VH-CDR2 artificial VISYDGSNEFYADSVKG 863 Flt3 VH-CDR3 artificial GGEITMVRGVIGYYYYGMDV 864 Flt3 VL-CDR1 artificial RTSQSISSYLN 865 Flt3 VL-CDR2 artificial AASSLQS 866 Flt3 VL-CDR3 artificial LQHNSYPLT 867 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG EITMVRGVIGYYYYGMDVWGQGTTVTVSS 868 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGC GTKVDIK 869 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV binds to FLT3 ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG comprises a EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ polypeptide SPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVDI K 870 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV binding to CD3 and ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG FLT3 EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ SPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGCGTKVDI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 871 Flt3 VH-CDR1 artificial SYGMH 872 Flt3 VH-CDR2 artificial VISYDGSNEFYADSVKG 873 Flt3 VH-CDR3 artificial GGEITMVRGVIGYYYYGMDV 874 Flt3 VL-CDR1 artificial RASQGVRNNLV 875 Flt3 VL-CDR2 artificial GASTRAT 876 Flt3 VL-CDR3 artificial LQHNSYPLT 877 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG EITMVRGVIGYYYYGMDVWGQGTTVTVSS 878 Flt3 VL region artificial EIVMTQSPATLSVSPGERATLSCRASQGVRNNLVWYQQKPGQAPRLLIYG ASTRATGIPARFSGSGSGTEFTLTISSLQSEDFATYYCLQHNSYPLTFGC GTKVEIK 879 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV binds to FLT3 ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG comprises a EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVMTQ polypeptide SPATLSVSPGERATLSCRASQGVRNNLVWYQQKPGQAPRLLIYGASTRAT GIPARFSGSGSGTEFTLTISSLQSEDFATYYCLQHNSYPLTFGCGTKVEI K 880 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV binding to CD3 and ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG FLT3 EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVMTQ SPATLSVSPGERATLSCRASQGVRNNLVWYQQKPGQAPRLLIYGASTRAT GIPARFSGSGSGTEFTLTISSLQSEDFATYYCLQHNSYPLTFGCGTKVEI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 881 Flt3 VH-CDR1 artificial SYGMH 882 Flt3 VH-CDR2 artificial VISYDGSNKYYADSVKG 883 Flt3 VH-CDR3 artificial SYGMDV 884 Flt3 VL-CDR1 artificial RASQGISSWLA 885 Flt3 VL-CDR2 artificial AASSLQS 886 Flt3 VL-CDR3 artificial QQANSFPWT 887 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV ISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSY GMDVWGQGTTVTVSS 888 Flt3 VL region artificial DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGC GTKLEIK 889 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV binds to FLT3 ISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSY comprises a GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRVT polypeptide ITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQANSFPWTFGCGTKLEIK 890 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKCLEWVAV binding to CD3 and ISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSY FLT3 GMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSVSASVGDRVT ITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTD FTLTISSLQPEDFATYYCQQANSFPWTFGCGTKLEIKSGGGGSEVQLVES GGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRSKYNN YATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGNFGNS YISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVSPGGT VTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPARFSGS LLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 891 Flt3 VH-CDR1 artificial NVRMGVS 892 Flt3 VH-CDR2 artificial HIFSNDEKLYTTSLKS 893 Flt3 VH-CDR3 artificial IVGYGTGWYGYFDY 894 Flt3 VL-CDR1 artificial RASQDIRDDLG 895 Flt3 VL-CDR2 artificial ATSIRQS 896 Flt3 VL-CDR3 artificial LQHHSFPLT 897 Flt3 VH region artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL AHIFSNDEKLYTTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI VGYGTGWYGYFDYWGQGTQVTVSS 898 Flt3 VL region artificial DIQMTQSPSSLSASIGDRVTITCRASQDIRDDLGWYQREPGKAPKRLIYA TSIRQSGVPSRFSGSGSGTEFTLTISGLQPEDFATYFCLQHHSFPLTFGG GTKVDIK 899 second domain which artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKLYTTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI comprises a VGYGTGWYGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASIGDRVTITCRASQDIRDDLGWYQREPGKAPKRLIYATSIRQSGVPSR FSGSGSGTEFTLTISGLQPEDFATYFCLQHHSFPLTFGGGTKVDIK 900 Antibody construct artificial QVTLKESGPVLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKLYTTSLKSRLTISKDTSKSQVVLTMTNMDPEDTATYYCARI FLT3 VGYGTGWYGYFDYWGQGTQVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASIGDRVTITCRASQDIRDDLGWYQREPGKAPKRLIYATSIRQSGVPSR FSGSGSGTEFTLTISGLQPEDFATYFCLQHHSFPLTFGGGTKVDIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 901 Flt3 VH-CDR1 artificial YARMGVS 902 Flt3 VH-CDR2 artificial HISSNDEKSFSTALES 903 Flt3 VH-CDR3 artificial MPGDSNTWRGFFDY 904 Flt3 VL-CDR1 artificial RTSQTVTNSYIA 905 Flt3 VL-CDR2 artificial GTSTRAT 906 Flt3 VL-CDR3 artificial QKYGSSPLT 907 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKALEWL AHISSNDEKSFSTALESRLTISTDTSKSQMVLTMTNVDPVDTATYYCARM PGDSNTWRGFFDYWGQGTLVTVSS 908 Flt3 VL region artificial EIVMTQSPGTLSLSPGERATLSCRTSQTVTNSYIAWYQQRPGQAPRLLIY GTSTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQKYGSSPLTFG GGTKLEIK 909 second domain which artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKALEWL binds to FLT3 AHISSNDEKSFSTALESRLTISTDTSKSQMVLTMTNVDPVDTATYYCARM comprises a PGDSNTWRGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTL polypeptide SLSPGERATLSCRTSQTVTNSYIAWYQQRPGQAPRLLIYGTSTRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQKYGSSPLTFGGGTKLEIK 910 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTFSGFSLRYARMGVSWIRQPPGKALEWL binding to CD3 and AHISSNDEKSFSTALESRLTISTDTSKSQMVLTMTNVDPVDTATYYCARM FLT3 PGDSNTWRGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTL SLSPGERATLSGRTSQTVTNSYIAWYQQRPGQAPRLLIYGTSTRATGIPD RFSGSGSGTDFTLTISRLEPEDFAVYYCQKYGSSPLTFGGGTKLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VL 911 Flt3 VH-CDR1 artificial NVRMGVS 912 Flt3 VH-CDR2 artificial HISSNDEKSYSTSLRS 913 Flt3 VH-CDR3 artificial MPGDSNTWRGFFDY 914 Flt3 VL-CDR1 artificial RTSQSVNNNLA 915 Flt3 VL-CDR2 artificial GASTRAT 916 Flt3 VL-CDR3 artificial LQHNSYPLT 917 Flt3 VH region artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL AHISSNDEKSYSTSLRSRLTISTDTSKSQVVLTMTNMDPVDTATYYCARM PGDSNTWRGFFDYWGQGTLVTVSS 918 Flt3 VL region artificial EIVMTQSPATLSVSPGERATLSCRTSQSVNNNLAWYQQKPGQAPRLLIYG ASTRATGIPARFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 919 second domain which artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binds to FLT3 AHISSNDEKSYSTSLRSRLTISTDTSKSQVVLTMTNMDPVDTATYYCARM comprises a PGDSNTWRGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATL polypeptide SVSPGERATLSCRTSQSVNNNLAWYQQKPGQAPRLLIYGASTRATGIPAR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK 920 Antibody construct artificial QVTLKESGPTLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binding to CD3 and AHISSNDEKSYSTSLRSRLTISTDTSKSQVVLTMTNMDPVDTATYYCARM FLT3 PGDSNTWRGFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPATL SVSPGERATLSCRTSQSVNNNLAWYQQKPGQAPRLLIYGASTRATGIPAR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 921 Flt3 VH-CDR1 artificial NVRMGVS 922 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 923 Flt3 VH-CDR3 artificial MPEYSSGWSGAFDI 924 Flt3 VL-CDR1 artificial RASQDIRDDLG 925 Flt3 VL-CDR2 artificial GASTLQS 926 Flt3 VL-CDR3 artificial LQHNSYPLT 927 Flt3 VH region artificial QVTLKESGPMLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM PEYSSGWSGAFDIWGQGTMVTVSS 928 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYG ASTLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTRLEIK 929 second domain which artificial QVTLKESGPMLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM comprises a PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL polypeptide SASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTRLEIK 930 Antibody construct artificial QVTLKESGPMLVKPTETLTLTCTVSGFSLRNVRMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKSQVVLTLTNMDPVDTATYFCARM FLT3 PEYSSGWSGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSL SASVGDRVTITCRASQDIRDDLGWYQQKPGNAPKRLIYGASTLQSGVPSR FSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTRLEIKSGGG GSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWV ARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYC VRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEP SLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAP GTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTV L 931 Flt3 VH-CDR1 artificial NARMGVS 932 Flt3 VH-CDR2 artificial HIFSNDEKSYSTSLKS 933 Flt3 VH-CDR3 artificial MVGYGSGWYAYFDY 934 Flt3 VL-CDR1 artificial RSSQSLLHSNGYNYLY 935 Flt3 VL-CDR2 artificial EVSNRFS 936 Flt3 VL-CDR3 artificial MQALQTPLT 937 Flt3 VH region artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL AHIFSNDEKSYSTSLKSRLTISKDTSKRQVVLTMTNMDPVDTATYYCARM VGYGSGWYAYFDYWGQGTLVTVSS 938 Flt3 VL region artificial DIVMTQTPLSLSVTPGQPASISCRSSQSLLHSNGYNYLYWYLQKPGQPPQ LLIYEVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTP LTFGGGTKVEIK 939 second domain which artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binds to FLT3 AHIFSNDEKSYSTSLKSRLTISKDTSKRQVVLTMTNMDPVDTATYYCARM comprises a VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQTPLSL polypeptide SVTPGQPASISCRSSQSLLHSNGYNYLYWYLQKPGQPPQLLIYEVSNRFS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEI K 940 Antibody construct artificial QVTLKESGPALVKPTQTLTLTCTFSGFSLSNARMGVSWIRQPPGKALEWL binding to CD3 and AHIFSNDEKSYSTSLKSRLTISKDTSKRQVVLTMTNMDPVDTATYYCARM FLT3 VGYGSGWYAYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQTPLSL SVTPGQPASISCRSSQSLLHSNGYNYLYWYLQKPGQPPQLLIYEVSNRFS GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPLTFGGGTKVEI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 941 Flt3 VH-CDR1 artificial SYGMH 942 Flt3 VH-CDR2 artificial VISYDGSNEFYADSVKG 943 Flt3 VH-CDR3 artificial GGEITMVRGVIGYYYYGMDV 944 Flt3 VL-CDR1 artificial RASQSISSYLN 945 Flt3 VL-CDR2 artificial AASSLQS 946 Flt3 VL-CDR3 artificial LQHNSYPLT 947 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG EITMVRGVIGYYYYGMDVWGQGTTVTVSS 948 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVEIK 949 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binds to FLT3 ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG comprises a EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ polypeptide SPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEI K 950 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binding to CD3 and ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG FLT3 EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ SPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 951 Flt3 VH-CDR1 artificial SYGMH 952 Flt3 VH-CDR2 artificial VISYDGSNEFYADSVKG 953 Flt3 VH-CDR3 artificial GGEITMVRGVIGYYYYGMDV 954 Flt3 VL-CDR1 artificial RASQGVRNNLV 955 Flt3 VL-CDR2 artificial GASTRAT 956 Flt3 VL-CDR3 artificial LQHNSYPLT 957 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG EITMVRGVIGYYYYGMDVWGQGTTVTVSS 958 Flt3 VL region artificial EIVMTQSPATLSVSPGERATLSCRASQGVRNNLVWYQQKPGQAPRLLIYG ASTRATGIPARFSGSGSGTEFTLTISSLQSEDFATYYCLQHNSYPLTFGG GTKVEIK 959 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binds to FLT3 ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG comprises a EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVMTQ polypeptide SPATLSVSPGERATLSCRASQGVRNNLVWYQQKPGQAPRLLIYGASTRAT GIPARFSGSGSGTEFTLTISSLQSEDFATYYCLQHNSYPLTFGGGTKVEI K 960 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binding to CD3 and ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG FLT3 EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSEIVMTQ SPATLSVSPGERATLSCRASQGVRNNLVWYQQKPGQAPRLLIYGASTRAT GIPARFSGSGSGTEFTLTISSLQSEDFATYYCLQHNSYPLTFGGGTKVEI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 961 Flt3 VH-CDR1 artificial SYGMH 962 Flt3 VH-CDR2 artificial VISYDGSNEFYADSVKG 963 Flt3 VH-CDR3 artificial GGEITMVRGVIGYYYYGMDV 964 Flt3 VL-CDR1 artificial RTSQSISSYLN 965 Flt3 VL-CDR2 artificial AASSLQS 966 Flt3 VL-CDR3 artificial LQHNSYPLT 967 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG EITMVRGVIGYYYYGMDVWGQGTTVTVSS 968 Flt3 VL region artificial DIQMTQSPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVDIK 969 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binds to FLT3 ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG comprises a EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ polypeptide SPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDI K 970 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binding to CD3 and ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG FLT3 EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ SPSSLSASVGDRVTITCRTSQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 971 Flt3 VH-CDR1 artificial SYGMH 972 Flt3 VH-CDR2 artificial VISYDGSNEFYADSVKG 973 Flt3 VH-CDR3 artificial GGEITMVRGVIGYYYYGMDV 974 Flt3 VL-CDR1 artificial RASQSISSYLN 975 Flt3 VL-CDR2 artificial AASSLQS 976 Flt3 VL-CDR3 artificial LQHNSYPLT 977 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG EITMVRGVIGYYYYGMDVWGQGTTVTVSS 978 Flt3 VL region artificial DIQMTQSPSSLSASVGNRVTITCRASQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGG GTKVDIK 979 second domain which artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binds to FLT3 ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG comprises a EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ polypeptide SPSSLSASVGNRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDI K 980 Antibody construct artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV binding to CD3 and ISYDGSNEFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGG FLT3 EITMVRGVIGYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQ SPSSLSASVGNRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVDI KSGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGK GLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDT AVYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTV VTQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGT KFLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGG TKLTVL 981 Flt3 VH-CDR1 artificial SYGMH 982 Flt3 VH-CDR2 artificial VISYDGSNKYYADSVKG 983 Flt3 VH-CDR3 artificial SYGMDV 984 Flt3 VL-CDR1 artificial RASQGISSWLA 985 Flt3 VL-CDR2 artificial AASSLQS 986 Flt3 VL-CDR3 artificial QQANSFPWT 987 Flt3 VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAV ISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARSY GMDVWGQGTTVTVSS 988 Flt3 VL region artificial DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQ GTKLEIK 989 scFv artificial qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvav isydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsy gmdvwgqgttvtvssggggsggggsggggsdiqmtqspssvsasvgdrvt itcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtd ftltisslqpedfatyycqqansfpwtfgqgtkleik 990 bispecific artificial qvqlvesgggvvqpgrslrlscaasgftfssygmhwvrqapgkglewvav molecule isydgsnkyyadsvkgrftisrdnskntlylqmnslraedtavyycarsy gmdvwgqgttvtvssggggsggggsggggsdiqmtqspssvsasvgdrvt itcrasqgisswlawyqqkpgkapklliyaasslqsgvpsrfsgsgsgtd ftltisslqpedfatyycqqansfpwtfgqgtkleiksggggsevqlves ggglvqpggslklscaasgftfnkyamnwvrqapgkglewvarirskynn yatyyadsvkdrftisrddskntaylqmnnlktedtavyycvrhgnfgns yisywaywgqgtlvtvssggggsggggsggggsqtvvtqepsltvspggt vtitcgsstgavtsgnypnwvqqkpgqaprgliggtkflapgtparfsgs llggkaaltlsgvqpedeaeyycvlwysnrwvfgggtkltvl 991 hu lsp V5xFlt3 artificial NQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVY E1muxEpC-pEF DHFR EA 992 FLT3 human MPALARDGGQLPLLVVFSAMIFGTITNQDLPVIKCVLINHKNNDSSVGKS SSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGN ISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEAT NYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCD SQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLN QTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEM STYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFI NATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNG YSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQA SCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSST LNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNISFYATIGV CLLFIVVLTLLICHKYKKQFRYESQLQMVQVTGSSDNEYFYVDFREYEYD LKWEFPRENLEFGKVLGSGAFGKVMNATAYGISKTGVSIQVAVKMLKEKA DSSEREALMSELKMMTQLGSHENIVNLLGACTLSGPIYLIFEYCCYGDLL NYLRSKREKFHRTWTEIFKEHNFSFYPTFQSHPNSSMPGSREVQIHPDSD QISGLHGNSFHSEDEIEYENQKRLEEEEDLNVLTFEDLLCFAYQVAKGME FLEFKSCVHRDLAARNVLVTHGKVVKICDFGLARDIMSDSNYVVRGNARL PVKWMAPESLFEGIYTIKSDVWSYGILLWEIFSLGVNPYPGIPVDANFYK LIQNGFKMDQPFYATEEIYIIMQSCWAFDSRKRPSFPNLTSFLGCQLADA EEAMYQNVDGRVSECPHTYQNRRPFSREMDLGLLSPQAQVEDS 993 PSMA-UniProt human MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEAT entry Q04609 NITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQW KEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPG YENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKI VIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPG GGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYY DAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTN EVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVR SFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYI NADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKK SPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYP LYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDY AVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERL QDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKY AGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA 994 PM 76-B10.17 CC VH artificial DYYMY CDR1 995 PM 76-B10.17 CC VH artificial IISDAGYYTYYSDIIKG CDR2 996 PM 76-B10.17 CC VH artificial GFPLLRHGAMDY CDR3 997 PM 76-B10.17 CC VL artificial KASQNVDANVA CDR1 998 PM 76-B10.17 CC VL artificial SASYVYW CDR2 999 PM 76-B10.17 CC VL artificial QQYDQQLIT CDR3 1000 PM 76-B10.17 CC VH artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF PLLRHGAMDYWGQGTLVTVSS 1001 PM 76-B10.17 CC VL artificial DIQMTQSPSSLSASVGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYS ASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGC GTKLEIK 1002 PM 76-B10.17 CC artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI SCEV ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK 1003 PM 76-B10.17 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 bispecific ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF molecule PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1004 PM 76-B10.17 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 scFc ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1005 PM 76-B10.17 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0-scFc_delGK ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1006 PM 76-B10.17 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 CC (103/43)- ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF scFc bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS molecule VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1007 PM 76-B10.17 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 CC (103/43)- ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF SCFC bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VWDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1008 PM 76-B10.17 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 CC (103/43)- ISDAGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF scFc delGK PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS bispecific VGDRVTITCKASQNVDANVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG HLE molecule SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1009 PM 76-B10.11 CC VH artificial DYYMY CDR1 1010 PM 76-B10.11 CC VH artificial IISDGGYYTYYSDIIKG CDR2 1011 PM 76-B10.11 CC VH artificial GFPLLRHGAMDY CDR3 1012 PM 76-B10.11 CC VL artificial KASQNVDTNVA CDR1 1013 PM 76-B10.11 CC VL artificial SASYVYW CDR2 1014 PM 76-B10.11 CC VL artificial QQYDQQLIT CDR3 1015 PM 76-B10.11 CC VH artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGE PLLRHGAMDYWGQGTLVTVSS 1016 PM 76-B10.11 CC VL artificial DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYS ASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGG GTKLEIK 1017 PM 76-B10.11 CC artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI scFv ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIK 1018 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI I2C0 bispecific ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF molecule PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1019 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI I2C0-scFc ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1020 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI I2C0-scFc_delGK ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1021 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI I2C0 CC (103/43)- ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF scFc bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1022 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI I2C0 CC (103/43)- ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF scFc bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1023 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKGLEWVAI I2C0 CC (103/43)- ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF scFc delGK PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS bispecific VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG HLE molecule SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGGGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1024 PM 76-B10.11 CC x artificial DYYMY I2C0-scFc VH CDR1 1025 PM 76-B10.11 CC x artificial IISDGGYYTYYSDIIKG I2C0-scFc VH CDR2 1026 PM 76-B10.11 CC x artificial GFPLLRHGAMDY I2C0 scFc VH CDR3 1027 PM 76-B10.11 CC x artificial KASQNVDTNVA I2C0-scFc VL CDR1 1028 PM 76-B10.11 CC x artificial SASYVYW I2C0-scFc VL CDR2 1029 PM 76-B10.11 CC x artificial QQYDQQLIT I2C0-scFc VL CDR3 1030 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0-scFc VH ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF PLLRHGAMDYWGQGTLVTVSS 1031 PM 76-B10.11 CC x artificial DIQMTQSPSSLSASVGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYS I2C0-scFc VL ASYVYWDVPSRFSGSASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGC GTKLEIK 1032 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0-scFc scFv ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCKASQNVDTNVAWYOQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIK 1033 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0-scFc ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF bispecific molecule PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1034 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0-scFc ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1035 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0-scFc_delGK ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGE bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1036 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 CC (103/43)- ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF scFc bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1037 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 CC (103/43)- ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF SCFC bispecific PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS HLE molecule VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1038 PM 76-B10.11 CC x artificial QVQLVESGGGLVKPGESLRLSCAASGFTFSDYYMYWVRQAPGKCLEWVAI I2C0 CC (103/43)- ISDGGYYTYYSDIIKGRFTISRDNAKNSLYLQMNSLKAEDTAVYYCARGF ScFc_delGK PLLRHGAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS bispecific VGDRVTITCKASQNVDTNVAWYQQKPGQAPKSLIYSASYVYWDVPSRFSG HLE molecule SASGTDFTLTISSVQSEDFATYYCQQYDQQLITFGCGTKLEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYCGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQCPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1039 DLL3 human MVSPRMSGLLSQTVILALIFLPQTRPAGVFELQIHSFGPGPGPGAPRSPC SARLPCRLFFRVCLKPGLSEEAAESPCALGAALSARGPVYTEQPGAPAPD LPLPDGLLQVPFRDAWPGTFSFIIETWREELGDQIGGPAWSLLARVAGRR RLAAGGPWARDIQRAGAWELRFSYRARCEPPAVGTACTRLCRPRSAPSRC GPGLRPCAPLEDECEAPLVCRAGCSPEHGFCEQPGECRCLEGWTGPLCTV PVSTSSCLSPRGPSSATTGCLVPGPGPCDGNPCANGGSCSETPRSFECTC PRGFYGLRCEVSGVTCADGPCFNGGLCVGGADPDSAYICHCPPGFQGSNC EKRVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCEHDLDDCAGRAC ANGGTCVEGGGAHRCSCALGFGGRDCRERADPCAARPCAHGGRCYAHFSG LVCACAPGYMGARCEFPVHPDGASALPAAPPGLRPGDPQRYLLPPALGLL VAAGVAGAALLLVHVRRRGHSQDAGSRLLAGTPEPSVHALPDALNNLRTQ EGSGDGPSSSVDWNRPEDVDPQGIYVISAPSIYAREVATPLFPPLHTGRA GQRQHLLFPYPSSILSVK 1040 DLL3 CDR-H1 artificial SYYWS 1041 DLL3 CDR-H2 artificial YVYYSGTTNYNPSLKS 1042 DLL3 CDR-H3 artificial IAVTGFYFDY 1043 DLL3 CDR-L1 artificial RASQRVNNNYLA 1044 DLL3 CDR-L2 artificial GASSRAT 1045 DLL3 CDR-L3 artificial QQYDRSPLT 1046 DLL3 CDR-H1 artificial SYYWS 1047 DLLS CDR-H2 artificial YIYYSGRTNYYPSLKS 1048 DLL3 CDR-H3 artificial IAVAGFFFDY 1049 DLL3 CDR-L1 artificial RASQSVNKNYLA 1050 DLL3 CDR-L2 artificial GASSRAT 1051 DLL3 CDR-L3 artificial QQYDRSPLT 1052 DLL3 CDR-H1 artificial SFYWS 1053 DLL3 CDR-H2 artificial YIYYSGTTNYNPSLKS 1054 DLL3 CDR-H3 artificial IAVAGFFFDY 1055 DLL3 CDR-L1 artificial RASQSVNKNYLA 1056 DLL3 CDR-L2 artificial GASSRAT 1057 DLL3 CDR-L3 artificial QQYDRSPLT 1058 DLL3 CDR-H1 artificial SFYWS 1059 DLL3 CDR-H2 artificial YIYYSGTTNYNPSLKS 1060 DLL3 CDR-H3 artificial IAVAGFFFDY 1061 DLL3 CDR-L1 artificial RASQSVNKNYLA 1062 DLL3 CDR-L2 artificial GASSRAT 1063 DLL3 CDR-L3 artificial QQYDRSPLT 1064 DLL3 CDR-H1 artificial SFYWS 1065 DLL3 CDR-H2 artificial YIYYSGTTNYNPSLKS 1066 DLL3 CDR-H3 artificial IAVAGFFFDY 1067 DLL3 CDR-L1 artificial RASQSVNKNYLA 1068 DLL3 CDR-L2 artificial GASSRAT 1069 DLL3 CDR-L3 artificial QQYDRSPLT 1070 DLL3 CDR-H1 artificial SFYWS 1071 DLL3 CDR-H2 artificial YIYYSGTTNYNPSLKS 1072 DLL3 CDR-H3 artificial IAVAGFFFDY 1073 DLL3 CDR-L1 artificial RASQSVNKNYLA 1074 DLL3 CDR-L2 artificial GASSRAT 1075 DLL3 CDR-L3 artificial QQYDRSPLT 1076 DLL3 CDR-H1 artificial SYYWS 1077 DLL3 CDR-H2 artificial YIFYNGITNYNPSLKS 1078 DLL3 CDR-H3 artificial IHSGSFSFDY 1079 DLL3 CDR-L1 artificial RASQSVSRGYLA 1080 DLL3 CDR-L2 artificial GASSRAT 1081 DLL3 CDR-L3 artificial QQYDTSPIT 1082 DLL3 CDR-H1 artificial NAGMS 1083 DLL3 CDR-H2 artificial RIKNKIDGGTTDFAAPVKG 1084 DLL3 CDR-H3 artificial RGWYGDYFDY 1085 DLL3 CDR-L1 artificial RSSQSLLHSNGYNYLD 1086 DLL3 CDR-L2 artificial LGSNRAS 1087 DLL3 CDR-L3 artificial MQALQTPFT 1088 DLL3 CDR-H1 artificial SYDIH 1089 DLL3 CDR-H2 artificial VISSHGSNKNYARSVKG 1090 DLL3 CDR-H3 artificial DGYSGNDPFYYYYHGMDV 1091 DLL3 CDR-L1 artificial RASQSISSYLN 1092 DLL3 CDR-L2 artificial AASSLQS 1093 DLL3 CDR-L3 artificial QQSFTTPLT 1094 DLL VH region artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSS 1095 DLL VH region artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IYYSGRTNYYPSLKSRVTISIDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSS 1096 DLL VH region artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSS 1097 DLL VH region artificial QVQLQESGPGLVKPSQTLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSS 1098 DLL VH region artificial QVQLQEWGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQLSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSK 1099 DLL VH region artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSS 1100 DLL VH region artificial QVQLQESGPGLVKPSQTLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IFYNGITNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAKYYCARIHS GSFSFDYWDQGTLVTVSS 1101 DLL VH region artificial EVQLVESGGGLVKPGGSLRLSCAASGFIFNNAGMSWVRQAPGKGLEWVGR IKNKIDGGTTDFAAPVKGRFTISRDDSKNTLYLQMNSLKAEDTAVYYCTA RGWYGDYFDYWGQGTLVTVSS 1102 DLL VH region artificial QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYDIHWVRQAPGKGLEWVAV ISSHGSNKNYARSVKGRFTISRDNSKNTLYLQMNSLKAEDTAVYYCARDG YSGNDPFYYYYHGMDVWGQGTTVTVSS 1103 DLL VH region artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSS529 1104 DLL VH region artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKCLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSS 1105 DLL VL REGION artificial EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG GGTKLEIK 1106 DLL VL REGION artificial EIVLTQSPGTLSLSPGERATLSCRASQSVNKNYLAWYQQKPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG GGTKLEIK 1107 DLL VL REGION artificial EIVLTQSPGTLSLSPGERATLSCRASQSVNKNYLAWYQQKPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG GGTKVEIK 1108 DLL VL REGION artificial EIVLTQSPGTLSLSPGERATLSCRASQSVNKNYLAWYQQKPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG GGTKVEIK 1109 DLL VL REGION artificial EIVLTQSPGTLSLSPGERATLSCRASQSVNKNYLAWYQQKPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG GGTKVDIK88 1110 DLL VL REGION artificial EIVLTQSPGTLSLSPGESATLSCRASQSVNKNYLAWYQQKPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG GGTRLEIK 1111 DLL VL REGION artificial EIVMTQSPGTLSLSPGERATLSCRASQSVSRGYLAWYQQKPGQAPRLLIY GASSRATDIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDTSPITFG QGTKVEIK 1112 DLL VL REGION artificial DIVMTQTPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQ LLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALQTP FTFGPGTKVEIK 1113 DLL VL REGION artificial DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSFTTPLTFGG GTKVEIK 1114 DLL VL REGION artificial EIVLTQSPGTLSLSPGERVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG CGTKLEIK 1115 DLL VL REGION artificial EIVLTQSPGTLSLSPGERATLSCRASQSVNKNYLAWYQQKPGQAPRLLIY GASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFG CGTKVEIK 1116 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIK 1117 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IYYSGRTNYYPSLKSRVTISIDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIK59 1118 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIK 1119 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSQTLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYOQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIK 1120 DLL BINDING DOMAIN artificial QVQLQEWGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQLSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVDIK 1121 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE SATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTRLEIK 1122 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSQTLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IFYNGITNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAKYYCARIHS GSFSFDYWDQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGE RATLSCRASQSVSRGYLAWYQQKPGQAPRLLIYGASSRATDIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDTSPITFGQGTKVEIK 1123 DLL BINDING DOMAIN artificial EVQLVESGGGLVKPGGSLRLSCAASGFIFNNAGMSWVRQAPGKGLEWVGR IKNKIDGGTTDFAAPVKGRFTISRDDSKNTLYLQMNSLKAEDTAVYYCTA RGWYGDYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQTPLSLPVT PGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVP DRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALQTPFTFGPGTKVEIK 1124 DLL BINDING DOMAIN artificial QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYDIHWVRQAPGKGLEWVAV ISSHGSNKNYARSVKGRFTISRDNSKNTLYLQMNSLKAEDTAVYYCARDG YSGNDPFYYYYHGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSFTTPLTFGGGTKVEIK 1125 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIK 1126 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKCLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKVEIK 1127 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1128 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IYYSGRTNYYPSLKSRVTISIDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1129 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1130 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSQTLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1131 DLL BINDING DOMAIN artificial QVQLQEWGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQLSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVDIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1132 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE SATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTRLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1133 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSQTLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IFYNGITNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAKYYCARIHS GSFSFDYWDQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGE RATLSCRASQSVSRGYLAWYQQKPGQAPRLLIYGASSRATDIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDTSPITFGQGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1134 DLL BINDING DOMAIN artificial EVQLVESGGGLVKPGGSLRLSCAASGFIFNNAGMSWVRQAPGKGLEWVGR IKNKIDGGTTDFAAPVKGRFTISRDDSKNTLYLQMNSLKAEDTAVYYCTA RGWYGDYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIVMTQTPLSLPVT PGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVP DRFSGSGSGTDFTLKISRVEAEDVGIYYCMQALQTPFTFGPGTKVEIKSG GGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLE WVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVY YCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQ EPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFL APGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKL TVL 1135 DLL BINDING DOMAIN artificial QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYDIHWVRQAPGKGLEWVAV ISSHGSNKNYARSVKGRFTISRDNSKNTLYLQMNSLKAEDTAVYYCARDG YSGNDPFYYYYHGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSP SSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGV PSRFSGSGSGTDFSLTISSLQPEDFATYYCQQSFTTPLTFGGGTKVEIKS GGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGL EWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAV YYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVT QEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKF LAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTK LTVL 1136 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1137 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IYYSGRTNYYPSLKSRVTISIDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1138 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1139 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSQTLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1140 DLL BINDING DOMAIN artificial QVQLQEWGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQLSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVDIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1141 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE SATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTRLEIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1142 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSQTLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY IFYNGITNYNPSLKSRVTISLDTSKNQFSLKLSSVTAADTAKYYCARIHS GSFSFDYWDQGTLVTVSSGGGGSGGGGSGGGGSEIVMTQSPGTLSLSPGE RATLSCRASQSVSRGYLAWYQQKPGQAPRLLIYGASSRATDIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDTSPITFGQGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCVRHGN FGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1143 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGY VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1144 DLL BINDING DOMAIN artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKCLEWIGY IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVL 1145 DLL EPITOPE REGION artificial RVDRCSLQPCRNGGLCLDLGHALRCRCRAGFAGPRCE 1146 DLL3 CDR-H1 artificial SYYMH 1147 DLL3 CDR-H2 artificial IINPSDGSTNYAQNFQG 1148 DLL3 CDR-H3 artificial GGNSAFYSYYDMDV 1149 DLL3 CDR-L1 artificial RSSQSLVYRDGNTYLS 1150 DLL3 CDR-L2 artificial KVSNWQS 1151 DLL3 CDR-L3 artificial MQGTHWPPT 1152 DLL3 CDR-H1 artificial NYYMH 1153 DLL3 CDR-H2 artificial IINPSDGSTSYAQKFQG 1154 DLL3 CDR-H3 artificial GGNSAFYSYYDMDV 1155 DLL3 CDR-L1 artificial RSSQSLVYRDGNTYLS 1156 DLL3 CDR-L2 artificial KVSNWQS 1157 DLL3 CDR-L3 artificial MQGTHWPPT 1158 DLL3 CDR-H1 artificial GYYIH 1159 DLL3 CDR-H2 artificial IINPSDGSTSYGQNFQG 1160 DLL3 CDR-H3 artificial GGNSAFYSYYDMDV 1161 DLL3 CDR-L1 artificial RSSQSLAYRDGNTYLS 1162 DLL3 CDR-L2 artificial KVSNWQS 1163 DLL3 CDR-L3 artificial MQGTHWPPT 1164 DLL3 CDR-H1 artificial GHYMH 1165 DLL3 CDR-H2 artificial IINPSDGSTNYAQKFQG 1166 DLL3 CDR-H3 artificial GTTWHYSYYDMDV 1167 DLL3 CDR-L1 artificial RSSQSLVYRDGNTYLT 1168 DLL3 CDR-L2 artificial KVSNWQS 1169 DLL3 CDR-L3 artificial MQGTHWPPT 1170 DLL3 CDR-H1 artificial NYFMH 1171 DLL3 CDR-H2 artificial IINPSDGSTSYAQNFQG 1172 DLL3 CDR-H3 artificial GGNSAFYSYYDMDV 1173 DLL3 CDR-L1 artificial RSSQSLVYRDGNTYLS 1174 DLL3 CDR-L2 artificial RVSNWQS 1175 DLL3 CDR-L3 artificial MQGTYWPPT 1176 DLL3 CDR-H2 artificial IINPSEGSTSYAQKFQG 1177 DLL3 CDR-H2 artificial IINPSDASTSYAQKFQG 1178 DLL CDR-L1 artificial RSSQSLVYREGNTYLS 1179 DLL CDR-L1 artificial RSSQSLVYRDANTYLS 1180 DLL CDR-L1 artificial RSSQSLVYRDGQTYLS 1181 DLL CDR-L1 artificial RSSQSLVYRDGNAYLS 1182 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGI INPSDGSTNYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1183 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1184 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGI INPSDGSTSYGQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1185 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGHYMHWVRQAPGQGLEWMGI INPSDGSTNYAQKFQGRVTMTRDTSTSTVYMELRSLRSEDTAVYYCTRGT TVVHYSYYDMDVWGQGTTVTVSS 1186 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYFMHWVRQAPGLGLEWMGI INPSDGSTSYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1187 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1188 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1189 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1190 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1191 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVS 1192 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1193 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1194 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1195 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1196 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1197 DLL3 VH REGION artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG NSAFYSYYDMDVWGQGTTVTVSS 1198 DLL3 VL REGION artificial DVVMTQSPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWP PTFGQGTKVEIK 1199 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1200 DLL3 VL REGION artificial DVVMTQSPLSLPVTLGQPASISCRSSQSLAYRDGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWP PTFGQGTKVEIK 1201 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLTWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGGGTKVEIK 1202 DLL3 VL REGION artificial DVVMTQSPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPR RLIYRVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTYWP PTFGQGTKVDIK 1203 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1204 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1205 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1206 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1207 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1208 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1209 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGQGTKVEIK 1210 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1211 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1212 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1213 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1214 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1215 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1216 DLL3 VL REGION artificial DWMTQTPLSLPVTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1217 DLL3 VL REGION artificial DVVMTQTPLSLPVTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPR RLIYKVSNWQSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWP PTFGCGTKVEIK 1218 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTNYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPPTFGQGTKVEIK 1219 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1220 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYGQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLAYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPPTFGQGTKVEIK 1221 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGHYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTNYAQKFQGRVTMTRDTSTSTVYMELRSLRSEDTAVYYCTRGT DOMAIN TVVHYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLTWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGGGTKVEIK 1222 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYFMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYRVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTYWPPTFGQGTKVDIK 1223 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1224 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1225 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1226 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1227 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1228 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1229 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1230 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1231 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1232 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1233 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK 1234 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1235 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1236 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1237 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1238 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1239 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1240 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1241 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1242 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1243 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1244 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1245 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK 1246 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTNYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1247 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1248 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYGQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLAYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1249 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGHYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTNYAQKFQGRVTMTRDTSTSTVYMELRSLRSEDTAVYYCTRGT DOMAIN TVVHYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLTWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGGGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1250 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYFMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYRVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTYWPPTFGQGTKVDIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1251 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTNYAQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTA VYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1252 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTA VYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1253 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYIHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYGQNFQGRVTMTRDTSTNTVYMELSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQSPLSLP VTLGQPASISCRSSQSLAYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYFCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFNSYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKGRFTISRDDSKNTAYLQMNSLKTEDTA VYYCVRHGNFGNSYVSWWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1254 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1255 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1256 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1257 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1258 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1259 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1260 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1261 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLGLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1262 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1263 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1264 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQGLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGQGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1265 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1266 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1267 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1268 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGQTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1269 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNAYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1270 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1271 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1272 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1273 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGLCLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGGGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1274 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSDGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1275 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSEGSTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYREGNTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1276 DLL3 ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYYMHWVRQAPGQCLEWMGI CONSTRUCT BINDING INPSDASTSYAQKFQGRVTMTRDTSTNTVYMDLSSLRSEDTAVYYCARGG DOMAIN NSAFYSYYDMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDVVMTQTPLSLP VTLGQPASISCRSSQSLVYRDANTYLSWFQQRPGQSPRRLIYKVSNWQSG VPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQGTHWPPTFGCGTKVEIK SGGGGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKG LEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTA VYYCVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVV TQEPSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTK FLAPGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGT KLTVL 1277 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY CONSTRUCT BINDING VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV DOMAIN TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1278 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKGLEWIGY CONSTRUCT BINDING VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV DOMAIN TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1279 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGY CONSTRUCT BINDING VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV DOMAIN TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1280 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGGSISSYYWSWIRQPPGKCLEWIGY CONSTRUCT BINDING VYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCASIAV DOMAIN TGFYFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RVTLSCRASQRVNNNYLAWYQQRPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKLEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1281 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY CONSTRUCT BINDING IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV DOMAIN AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1282 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKGLEWIGY CONSTRUCT BINDING IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV DOMAIN AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGGGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1283 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKCLEWIGY CONSTRUCT BINDING IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV DOMAIN AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1284 DLL3 ANTIBODY artificial QVQLQESGPGLVKPSETLSLTCTVSGASISSFYWSWIRQPPGKCLEWIGY CONSTRUCT BINDING IYYSGTTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARIAV DOMAIN AGFFFDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSPGTLSLSPGE RATLSCRASQSVNKNYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSG SGTDFTLTISRLEPEDFAVYYCQQYDRSPLTFGCGTKVEIKSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGGSGGGGSGGGGSGGGGS GGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD VSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLN GKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSL TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKS RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1285 BCMA ANTIBODY artificial GYYMH CONSTRUCT HCDR1 1286 BCMA ANTIBODY artificial WINPNSGGTKYAQKFQG CONSTRUCT HCDR2 1287 BCMA ANTIBODY artificial DRITVAGTYYYYGMDV CONSTRUCT HCDR3 1288 BCMA ANTIBODY artificial RASQGVNNWLA CONSTRUCT LCDR1 1289 BCMA ANTIBODY artificial TASSLQS CONSTRUCT LCDR2 1290 BCMA ANTIBODY artificial QQANSFPIT CONSTRUCT LCDR3 1291 BCMA ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGW CONSTRUCT VH REGION INPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDR ITVAGTYYYYGMDVWGQGTTVTVSS 1292 BCMA ANTIBODY artificial DIQMTQSPSSVSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYT CONSTRUCT VL REGION ASSLQSGVPSRFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGC GTRLEIK 1293 BCMA ANTIBODY artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHIIHWVRQAPGQCLEWMGY CONSTRUCT BINDING INPYPGYHAYNEKFQGRATMTSDTSTSTVYMELSSLRSEDTAVYYCARDG DOMAIN YYRDTDVLDYWGQGTLVTVSSGGGGSGGGGSGGGGSDIQMTQSPSSLSAS VGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYYTSRLHTGVPSRFSG SGSGTDFTFTISSLEPEDIATYYCQQGNTLPWTFGCGTKVEIKSGGGGSE VQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARI RSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRH GNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLT VSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTP ARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGG GGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSH EDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKE YKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQ QGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSG GGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQ DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLT VDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1294 CLAUDIN 18.2 artificial QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQCLEWMGW ANTIBODY CONSTRUCT INPNSGGTKYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARDR BINDING DOMAIN ITVAGTYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQMTQSPSS VSASVGDRVTITCRASQGVNNWLAWYQQKPGKAPKLLIYTASSLQSGVPS RFSGSGSGTDFTLTIRSLQPEDFATYYCQQANSFPITFGCGTRLEIKSGG GGSEVQLVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEW VARIRSKYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYY CVRHGNFGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQE PSLTVSPGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLA PGTPARFSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLT VLGGGGDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVV DVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWL NGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVS LTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGG GGSGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTP EVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLT VLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLY SKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK 1295 MUCIN 17 ANTIBODY artificial QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKCLEWIGD CONSTRUCT BINDING IDASGSTKYNPSLKSRVTISLDTSKNQFSLKLNSVTAADTAVYFCARKKY DOMAIN STVWSYFDNWGQGTLVTVSSGGGGSGGGGSGGGGSSYELTQPSSVSVPPG QTASITCSGDKLGDKYASWYQQKPGQSPVLVIYQDRKRPSGVPERFSGSN SGNTATLTISGTQAMDEADYYCQAWGSSTAVFGCGTKLTVLSGGGGSEVQ LVESGGGLVQPGGSLKLSCAASGFTFNKYAMNWVRQAPGKGLEWVARIRS KYNNYATYYADSVKDRFTISRDDSKNTAYLQMNNLKTEDTAVYYCVRHGN FGNSYISYWAYWGQGTLVTVSSGGGGSGGGGSGGGGSQTVVTQEPSLTVS PGGTVTLTCGSSTGAVTSGNYPNWVQQKPGQAPRGLIGGTKFLAPGTPAR FSGSLLGGKAALTLSGVQPEDEAEYYCVLWYSNRWVFGGGTKLTVLGGGG DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED PEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSGGGGSGGG GSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV VDVSHEDPEVKFNWYVDGVEVHNAKTKPCEEQYGSTYRCVSVLTVLHQDW LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK